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180. UTILITY OF BODY WEIGHT CLASSIFIED LOW-DOSE
LEFLUNOMIDE IN JAPANESE RHEUMATOID ARTHRITIS
Masataka Nishikawa1, Hajime Owaki2 and Takeshi Fuji1
1Orthopaedic Surgery, Osaka Koseinenkin Hospital, Osaka City,
Osaka, Japan; 2Rheumatology, Osaka Koseinenkin Hospital, Osaka
City, Osaka, Japan
Background: In Japan, more than 20 rheumatoid arthritis (RA) patients
died of interstitial pneumonia (IP) caused by leflunomide (LEF) were
reported, but many of them were considered as the victims of
opportunistic infection currently. In this paper, efficacy and safety of
low-dose LEF classified by body weight (BW) were studied.
Methods: Fifty-nine RA patients were started to administrate LEF from
July 2007 to July 2009. Among them, 25 patients were excluded
because of the combination with tacrolimus, and medication mod-
ification within 3 months before LEF. Remaining 34 RA patients
administered 20 to 50 mg/week of LEF were followed up for 1 year and
enrolled in this study. Dose of LEF was classified by BW (50 mg/week
for over 50 kg, 40 mg/week for 40 to 50 kg and 20 to 30 mg/week for
under 40 kg). The average age and RA duration of enrolled patients
were 55.5 years old and 10.2 years. Prednisolone (PSL), methotrexate
(MTX) and etanercept were used in 23, 28 and 2 patients, respectively.
In case of insufficient response or adverse effect, dosage change or
discontinuance of LEF were considered. Failure was defined as
dosages up of PSL and MTX, or dosages down or discontinuance of
LEF. Last observation carried forward method was used for the
evaluation of failed patients at 1 year.
Results: At 1 year after LEF start, good/ moderate/ no response
assessed by the European League Against Rheumatism (EULAR)
response criteria using Disease Activity Score, including a 28-joint
count (DAS28)-C reactive protein (CRP) were showed in 14/ 10/ 10
patients, respectively. The dosage changes of LEF at 1 year were
dosage up: 10, same dosage: 5, dosage down: 8 and discontinuance:
11 patients. The survival rate of patients in this study was 23.5% (24
patients failed) but actual LEF continuous rate was 67.6% (11 patients
discontinued) at 1 year. The major reason of failure was liver
dysfunction, and pneumocystis pneumonia was occurred in 1 patient
resulted in full recovery. One patient died of sepsis caused by
decubitus ulcer infection. DAS28-CRP score was decreased from 3.9
to 2.7 significantly. Although CRP was decreased from 1.50 to
0.93 mg/dl, it wasn’t significant. Matrix metalloproteinase (MMP)-3
was decreased from 220.0 to 174.2 ng/ml significantly. Glutamate
pyruvate transaminase (GPT) was increased from 19 to 35 U/l and
number of leukocyte was decreased from 7832 to 6271 significantly.
DAS28-CRP, CRP, and MMP-3 were improved significantly with MTX,
although they weren’t without MTX. Increase of GPT and leukopenia
were seen significantly with MTX, although they weren’t without MTX.
Conclusions: It was reported that the risks of IP caused by LEF in
Japanese RA patients were past IP history, loading dose administra-
tion and low BW. Addition of low-dose LEF is a potent safe alternative
for the patients showing unsatisfactory response to current medicines,
but need to pay attention for liver function and infection caused by
leukopenia, especially with MTX.
Disclosure statement: The authors have declared no conflicts of
interest.
181. PREDICTORS OF RESPONSE TO RITUXIMAB IN
PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS
FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY
BIOLOGICS REGISTER (BSRBR)
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Mark Lunt2, Deborah Symmons2 and Kimme L. Hyrich2
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of Manchester, Manchester, United Kingdom; 2Arthritis Research
UK Epidemiology Unit, The University of Manchester, Manchester,
United Kingdom
Background: Rituximab (RTX) has proven efficacy in the management
of rheumatoid arthritis (RA) in both clinical trials and observational
studies. Identifying the factors that are associated with better
response to RTX is important to optimise its use in clinical practice.
This analysis aimed to identify predictors of six month response to RTX
and disease remission, in routine clinical practice, in RA patients who
had failed traditional non-biologic Disease Modifying Anti-Rheumatic
Drugs (nbDMARDs) and at least one anti-Tumor Necrosis Factor
(anti-TNF) therapies.
Methods: The analysis involved 463 patients with RA prospectively
registered with the BSRBR; an observational cohort study. Univariate
and multivariate linear regression models were used to identify factors
associated with the change in Disease Activity Score (DAS28) after
6 months from starting RTX. Stepwise selection was used to select
the covariates to be included in the multivariate models based on a
significance level of 0.05. Univariate and multivariate logistic regres-
sion models were used to identify factors associated with achieving
disease remission (DAS28<2.6). The models examined (i) baseline
demographics [age, gender, current smoking, presence of co-
morbidities], (ii) baseline disease characteristics [disease duration,
rheumatoid factor (RF), DAS28], (iii) baseline quality of life [Health
assessment Questionnaire (HAQ), European Quality of life 5
Dimensions (EQ5D) utility score], (iv) baseline concurrent therapy
[concurrent steroid, concurrent nbDMARDs (no nbDMARD, metho-
trexate, or other nbDMARDs)], and (v) previous drug history [previous
steroid, number of previous nbDMARDs, the type of the most recently
stopped anti-TNF therapy (etanercept or monoclonal antibody),
number of failed anti-TNF therapies, the reason for stopping the last
anti-TNF therapy (inefficacy, adverse event or other reasons)].
Results: In the multivariate analysis, subjects with higher baseline
DAS28 were more likely to respond to the therapy (p< 0.001), as
measured by the change in DAS28, while patients with higher physical
disability were less likely to respond (p¼0.001). RF positive patients
were more likely to achieve disease remission while patients with
higher baseline physical disability or higher baseline DAS28 were less
likely to achieve remission (Table 1). Current smokers showed
tendency towards not achieving disease remission (p¼0.06).
Conclusions: In routine clinical practice, response to RTX was
influenced by baseline disease activity and baseline physical function.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
Significant predictors of change
in DAS28








0.56 (-0.68, -0.44) Baseline DAS28 0.69 (0.47, 0.99)
Baseline
HAQ
0.38 (0.15, 0.61) Baseline HAQ 0.31 (0.15, 0.65)
– – RF positive patient 3.69 (1.01, 13.64)
182. ARE GUIDELINES FOR THE MANAGEMENT
OF RHEUMATOID ARTHRITIS BEING MET?
Francesca Atkinson1, Saadia Malik1, Carol Heycock1,
Vadivelu Saravanan1, Martin Rynne1, Jennifer Hamilton1 and
Clive Kelly1
1Rheumatology, QEH Gateshead, Gateshead, United Kingdom
Background: NICE currently recommends aggressive therapy with
combination DMARDs in rheumatoid arthritis (RA) as opposed to step
up treatment starting with monotherapy. The British Society of
Rheumatology (BSR) has advised that a DAS28 >3.2 warrants
escalation or change of treatment using a ‘treat to target’ approach.
We were interested in assessing the mean DAS in our patients on
different clusters of therapy to see whether disease control related to
the therapeutic regime. We also wished to assess the value of
performing real time DAS scores in clinic to aid treating to target.
Methods: Data was collected from 170 patients with RA attending
consecutive outpatient review clinics. Information was collected on
DAS28 scores, prognostic factors (rheumatoid factor, anti-CCP,
nodules, smoking, erosions on x-ray), duration of RA, current
treatment, and all changes to treatment. Patients were divided into
clusters based on treatment and mean DAS scores calculated for each
treatment group. Prognostic factors were also ranked against DAS
scores and treatment group. Changes in treatment were noted in
relation to DAS score in clinic.
Results: The group comprised 71% females with a mean age of 63
(range 32 to 90 years) and mean RA duration of 10 years. Monotherapy
was used in 57 (34%) patients and the mean DAS score was 2.8 in this
cluster. Combination DMARDs were used in 56 (33%) patients, with a
group mean DAS of 3.4. Biologic agents were used in 35 (21%) with a
mean DAS of 3.8., while parenteral methotrexate was used in 22 (12%)
with a mean DAS of 4.5. There was no correlation between the number
of adverse prognostic factors and DAS score. There was a strong
relationship between DAS score and the percentage of patients in
whom treatment was escalated at that clinic visit (Table 1)
Conclusions: Patients can enter remission on monotherapy. Our
results demonstrate that not all RA patients need aggressive first line
combination therapy as presently recommended. Prognostic factors
do not readily allow prediction of the level of treatment required to
achieve DAS remission in an individual. Treating to target does lead to
appropriate escalation in most patients and the use of DAS scores in
clinic to guide treatment change is valuable and practical.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Percentage of patients in each DAS category who had treatment
escalated
DAS <2.6 DAS 2.6-3.2 DAS 3.2-5.1 DAS >5.1
6 16 42 88
183. LOW DISEASE ACTIVITY DURING FOUR YEARS
OF ADALIMUMAB TREATMENT FOR PATIENTS WITH
RHEUMATOID ARTHRITIS WITH AND WITHOUT HISTORY
OF OTHER TUMOUR NECROSIS FACTOR-ANTAGONIST
THERAPIES
Gerd Burmester1, Sonja Kary2, Kristina Unnebrink2,
Benoit Gue´rette3, Uemit Oezer2 and Hartmut Kupper2
1University Medicine, Charite´, Berlin, Germany; 2Abbott, Abbott
GmbH & Co. KG, Ludwigshafen, Germany; 3Abbott France, Abbott,
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Background: Switching to a subsequent tumor necrosis factor
(TNF) antagonist is an effective treatment for patients with rheumatoid
arthritis (RA) after failure or intolerance of a prior anti-TNF therapy.
However, long-term data on disease activity after switching to
adalimumab are sparse. The objective was to investigate the
achievement of low disease activity (LDA) during 4 years of treatment
with adalimumab in patients with and without a history of anti-TNF
therapy, stratified by reason for discontinuation of the prior TNF
antagonist.
Methods: Data were analyzed from patients with and without a history
of infliximab and/or etanercept therapy who continued adalimumab
in an ongoing, 5-year observational study (ReAlise) after completion
of a multinational, uncontrolled, Phase 3b study (Research in Active
Rheumatoid Arthritis Trial [ReAct]), during which patients received
adalimumab therapy for 12 weeks. Treatment effectiveness was
measured by 28-joint Disease Activity Score (DAS28) LDA (DAS28
3.2) with last observation carried forward (LOCF) because of
decreasing numbers of patients with available data in this ongoing
study.
Results: Data were available for 408 patients with and 3,025 patients
without prior anti-TNF therapy. At ReAct baseline, mean (SD) DAS28
values in patients with and without prior anti-TNF therapy were 6.3
(1.1) and 5.9 (1.1), respectively. The mean (SD) changes in DAS28 from
baseline to month 48 were -2.7 (1.5) and -2.5 (1.6) (P<0.001 for
patients with and without prior anti-TNF treatment). In addition, 165
(40%) patients with and 1,652 (55%) patients without prior anti-TNF
therapy achieved LDA at month 48. Relative to patients without prior
anti-TNF therapy, those with prior anti-TNF therapy achieved LDA
somewhat later, mainly because the percentage of patients in LDA was
still relevantly increasing beyond month 12 for patients who discon-
tinued a prior TNF antagonist because of lack of response. After 2
years of adalimumab therapy, the percentages of patients in LDA were
similar irrespective of the reason for discontinuation of prior anti-TNF
therapy (Table 1).
Conclusions: Although the therapeutic responses to adalimumab
were greatest in patients without prior anti-TNF therapy, many patients
who switched to adalimumab after discontinuing prior anti-TNF
therapy achieved LDA during 4 years of adalimumab therapy, albeit
at a somewhat slower rate.
Disclosure statement: G.B. has received research grants and
consultancy fees and is/has been a member of a speakers’ bureau
for Abbott. B.G., H.K. and K.U. are employees of Abbott and own
Abbott stock or stock options. S.K. and U.O. are contract employees
of Abbott.
TABLE 1. Percentages of patients achieving LDA (LOCF) during 4 years of
















41.9 48.3 51.0 54.5 55.1 55.0
Prior anti-TNF therapy
(N¼ 408)
28.0 30.9 34.1 39.7 42.2 40.4
Lack of Response
(N¼ 76)
17.8 22.4 27.6 36.8 40.8 40.8
Loss of Response
(N¼ 142)
19.4 26.8 33.8 38.7 37.3 36.6
Intolerance (N¼ 87) 39.8 36.8 40.2 40.2 48.3 43.7
184. WHAT ROLE DOES GENDER PLAY IN ACCESS TO
BIOLOGIC AGENTS AND DOES IT INFLUENCE CHOICE
OF INDIVIDUAL AGENT?
Elaine Dennison1, Karen Jameson1, Kimme Hyrich2, Kath Watson2,
BSRBR Control Centre Consortium2, Deborah Symmons1 and
Cyrus Cooper1 on behalf of the BSR Biologics Register2
1MRC Lifecourse Epidemiology Unit, Southampton University,
Southampton, United Kingdom; 2Arthritis Research UK
Epidemiology Unit, Manchester University, Manchester,
United Kingdom
Background: While severe clinical disease activity, structural damage,
and deformities have been reported equally in both genders in
rheumatoid arthritis (RA), women typically report more severe
symptoms and greater disability, and often have higher work disability
rates compared with men. We utilised the British Society of
Rheumatology Biologics Register (BSRBR) to assess whether these
observations are translated into any difference in uptake in biologic
agents between the 2 sexes; we also assessed gender differences in
choice of individual agent.
Methods: The analysis included 10,749 subjects [2,545 (23.7%) men
and 8204 (76.3%) women] commenced on their first biologic agent
between 1999 and 2010 and registered with the BSRBR, a UK national
observational cohort study set up to monitor the long term safety of
biologic agents in patients with rheumatoid arthritis receiving antiTNF
therapy. We also studied 753 (27.3%) men and 2004 (72.7%) women
with active RA treated with traditional disease-modifying antirheumatic
drugs (DMARDs), and 48 (23.5%) men and 156 (76.5%) women who
switched from DMARDs to biologic agents.
Results: Both male and female cases who received biologic therapy
were younger and had higher DAS28 scores compared with patients
treated with traditional DMARDs recruited to the control arm. Women
who received biologic therapy were younger at treatment initiation
than their male counterparts [55.9 years (SD 12.4) versus 57.5 years
(SD 11.3) years, p<0.001]; they typically had also received more
traditional DMARDs prior to initiation of therapy and also had a longer
duration of illness (median 12 years versus 11 years, p<0.001).
However, this was not reflected in any difference in erosive disease
between the 2 sexes (69%, p¼0.85). Very similar patterns were seen
in the control group. Fourty eight (23.5%) men and 156 (76.5%) women
switched to biologic agents from DMARDs. The mean age at switching
was 58 years in both sexes; women had a longer duration of disease
(median 11 years vs. 7.5 years), but there was no difference in the
number of previous DMARDs used in men and women previously
(median 3). We found little difference in choice of individual biologic
agent used in either group.
Conclusions: In both sexes, patients with more severe disease
appeared to receive biologic agents. While women recorded higher
DAS28 scores, this was not reflected in a difference in recorded
erosive disease. There was little gender difference in choice of
individual biologic agent.
Disclosure statement: B.C., K.H., D.S. and K.W. have received
support for the BSRBR from Schering-Plough, Wyeth, Abbott and
Amgen. All other authors have declared no conflicts of interest.
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185. DISCONNECT BETWEEN DISEASE ACTIVITY AND
JOINT SPACE NARROWING FOR PATIENTS WITH EARLY RA
TREATED WITH ADALIMUMAB PLUS METHOTREXATE BUT
NOT METHOTREXATE ALONE: CASE FOR ANTI-TNF
CARTILAGE PROTECTION
Robert Landewe1, Edward Keystone2, Josef Smolen3,
Mary Goldring4, Benoit Gue´rette5, Kaushik Patra6, Mary Cifaldi6 and
De´sire´e van der Heijde7
1Department of Internal Medicine/Rheumatology, University Hospital
Maastricht, Maastricht, Netherlands; 2The Rebecca MacDonald
Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital,
University of Toronto, Toronto, ON, Canada; 3Department of
Rheumatology, Medical University of Vienna, Vienna, Austria;
4Department of Cell & Developmental Biology, Weill Cornell Medical
College, New York, NY, USA; 5Global Pharmaceutical Research and
Development, Abbott, Rungis, France; 6Global Pharmaceutical
Research and Development, Abbott, Abbott Park, IL, USA;
7Department of Rheumatology, Leiden University Medical Center,
Leiden, Netherlands
Background: Joint space narrowing (JSN) is inhibited by treatment
with the combination of adalimumab (ADA) and methotrexate (MTX).
Importantly, it is not known whether ADAþMTX treatment exerts
these protective effects solely by controlling inflammation or also by a
specific effect on cartilage as has been shown for joint erosions. The
objective of this analysis was to compare the relationship between
disease activity (DAS28) and progression of JSN in patients with early
rheumatoid arthritis (RA) treated with ADAþMTX vs. MTX.
Methods: Two-year data from the PREMIER study (a randomized
controlled trial comparing MTX with ADAþMTX in patients with early
RA) were used to perform this analysis. Data were from patients
(N¼525) randomized to MTX or ADAþMTX. DAS28 was time-
averaged (TA-DAS28) over 3 intervals from baseline: 26, 52, and 104
weeks, and multivariate analyses were performed to assess the impact
of treatment and TA-DAS28 on change in JSN after 26, 52, and 104
weeks of treatment. To control for continuous between-group
variations in DAS28, we compared groups by TA-DAS28 quartile.
Results: All results are changes in JSN expressed by quartile (range)
of TA-DAS28. In the MTX group, JSN increased as TA-DAS28
increased [Week 26 (observed): Q1 (<3.6): 0.38; Q2 (3.6-<4.4): 0.39;
Q3 (4.4-<5.1): 0.64; Q4 (5.1): 2.43. Week 52 (observed): Q1 (<3.2):
0.60; Q2 (3.2-<4.0): 1.05; Q3 (4.0-<4.8): 1.38; Q4 (4.8): 3.97. Week
104 (linear imputation): Q1 (<3.3): 0.82; Q2 (3.3-<4.2): 2.11; Q3 (4.2-
<5.1): 2.98; Q4 (5.1): 8.14]. However, this relationship was not
apparent in the ADAþMTX group [Week 26: Q1 (<3.6): 0.15; Q2 (3.6-
<4.4): 0.17; Q3 (4.4-<5.1): -0.06; Q4 (5.1): 0.63. Week 52: Q1 (<3.2):
0.52; Q2 (3.2-<4.0): 0.43; Q3 (4.0-<4.8): 0.55; Q4 (4.8): 0.53. Week
104: Q1 (<3.3): 0.56; Q2 (3.3-<4.2): 0.90; Q3 (4.2-<5.1): 1.02; Q4
(5.1): 1.60]. Wk-104 results were similar using either observed data or
linear imputation.
Conclusions: The typical relationship between TA-DAS28 and
progression of JSN was observed in patients treated with MTX;
however, this relationship was not apparent in patients treated with
ADAþMTX. These results suggest that ADAþMTX may have direct
protective effects on cartilage that are beyond its ability to control for
disease activity, potentially through the inhibition of catabolytic
activities in chondrocytes.
Disclosure statement: M.C., B.G. and K.P. are full-time employees of
Abbott and may hold Abbott stock or stock options. M.G. has received
research grants and honoraria from Abbott, research grants from
Merck Serono, consultancy fees or other remuneration from NicOx and
Pfizer, and honoraria from Fidia Farmaceutici. E.K. has received
consultancy fees or other remuneration from Abbott, UCB, Pfizer,
Roche, Amgen and Bristol-Myers Squibb. R.L. is/has been a member
of speakers’ bureaus for, and has received research grants,
consultancy fees or other remuneration from Abbott, Amgen,
Centocor, Pfizer/Wyeth, UCB and Bristol-Myers Squibb. J.S. has
received research grants, consultancy fees or other remuneration from
Abbott, Bristol-Myers Squibb, Centocor, Schering-Plough (MSD),
Roche, UCB and Pfizer/Wyeth. D.vdH. has received consultancy
fees or other remuneration from, Abbott, Amgen, Bristol-Myers
Squibb, Centocor, Chugai, Merck, Novartis, Pfizer, Roche, Sanofi-
Aventis, Schering-Plough, UCB and Wyeth.
186. MAINTAINING PATIENTS WITH RHEUMATOID
ARTHRITIS IN REMISSION ON REDUCED BIOLOGIC
THERAPY DOSAGE
Lois A. Lloyd1,2, Catherine Owen1, Anne Breslin1 and
Yasmeen Ahmad1
1Department of Rheumatology, Betsi Cadwaladr University
Healthboard, Bangor, United Kingdom; 2Department of Pharmacy,
Betsi Cadwaladr University Healthboard, Bangor, United Kingdom
Background: Treatment with biologic therapies such as tumour
necrosis factor (TNF) blockade has increased remission rates in
patients with rheumatoid arthritis (RA). The objective of this study was
to explore whether RA patients attending BCU-West Biologic clinic
could be maintained in remission on a reduced TNF blocker dosage.
Methods: Among 96 patients on TNF blocker therapy for RA, 26 had
their doses reduced as they had achieved remission. Remission was
defined as DAS28<2.6 for 6 months or longer. The original dose of
TNF blocker was restarted in the event of a relapse (DAS>3.2).
Results: A minimum of 6 month data was achieved for 20 out of the 26
patients. The other 6 patients were excluded from the analysis as they
had less than 6 months data. The TNF blocker therapy was etanercept
in 15 cases and adalimumab in the other 5 cases. Seven patients were
taking concomitant DMARD therapy (methotrexate n¼5, other n¼2)
and 2 patients were taking longterm prednisolone at a dose range of 5
- 7.5 mg daily. Fifty five per cent of the patients were female. The 20
patients had a mean age of 61.5 years (range 40-83 years), a mean
disease duration of 12.05 years (range 7-19 years) and a mean TNF
blocker therapy duration before dose reduction of 57.3 months (range
13-101 months). Sixty per cent of the 20 patients were rheumatoid
factor positive. The mean DAS28 score prior to starting TNF blocker
therapy was 5.49 (range 3.028 - 7.32). The number of patients still in
remission after TNF blocker dose reduction was 17/20 at 6 months. At
12 months, 12/17 (71%) patients remained in remission. Whilst on a
reduced dose, 3(18%) patients relapsed and returned to their original
dose of TNF blocker (etanercept¼3, rheumatoid factor positive¼3).
All 3 patients achieved remission on the original dosage. The 17
patients that remained in remission had varied reduced dosages.
Etanercept doses ranged from 50 mg/25 mg on alternate weeks to
25 mg monthly and adalimumab from 40 mg every 3 weeks to 40 mg
every 5 weeks. A total cost saving of £120,000 has been made by
reducing the doses of patients who achieved remission.
Conclusions: Maintenance of disease remission was achieved in 85%
and 71% of cases on a reduced dose of TNF blocker after 6 and 12
months respectively. Relapsing patients responded well to resumption
of original TNF blocker dosage. The optimal duration and dose of
expensive biologic agents in patients who attain remission is unknown.
There have been a number of studies that have shown relapes when
biologics agents have been discontinued but there is very little
information regarding reducing doses. As a first step we have shown
that clinical remission can be acheived with reduced biologic doses at
1 year. There is an economical and clinical need to explore these
issues, so more patients can be treated with these drugs without
massively increasing drug budgets within the NHS.
Disclosure statement: The authors have declared no conflicts of
interest.
187. POST-TREATMENT CHANGES IN SERUM C-REACTIVE
PROTEIN LEVELS AND CLINICAL RESPONSE IN
RHEUMATOID ARTHRITIS
Paul Emery1, E. L. Matteson2, M. Genovese3, S. Sague4, E.
C. Hsia5,6, M. K. Doyle5,6, H. Fan7, M. Elashoff8 and M. U. Rahman
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Centocor Research & Development, Inc., Malvern, PA, USA;
5Immunology, Centocor Research & Development, Inc., Malvern, PA,
USA; 6Rheumatology, University of Pennsylvania School of Medicine,
Philadelphia, PA, USA; 7Bioinformatics, Centocor Research &
Development, Inc., Malvern, PA, USA; 8Elashoff Consulting,
Redwood City, CA, USA
Background: With the availability of many effective therapies for RA,
biomarker(s) that can reliably predict response to a treatment would be
useful in clinical practice. Serum CRP levels have been known to be
associated with disease activity including radiographic progression. It
is however not clear if early changes in serum CRP levels in response
to treatment can predict sustained clinical response at later time
points. To evaluate if early post-treatment changes in CRP can reliably
predict clinical response, we evaluated the association of early post-
treatment changes in serum CRP levels with clinical response at a later
time point.
Methods: Sera were collected at wk0, 4 & 24 from GO-BEFORE (MTX
naı¨ve RA patients; 477 golimumab [GLM]þ/-MTX, 160PBOþMTX),
GO-FORWARD (active RA patients despite MTX; 311GLMþ/-MTX,
133PBOþMTX) and GO-AFTER (active RA patients previously treated
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with TNF inhibitors; 304GLM, 155PBO) studies. Samples were tested
for CRP levels using Roche Tinaquant assay. CRP levels at baseline
(BL), wk4 & 24 in GLMMTX and PBOþ/-MTX patients achieving and
not achieving multiple measures of clinical response (ACR & EULAR/
DAS response criteria) were evaluated. Logistic regression models
were used to test for marker associations with clinical endpts. Positive
predictive value (PPV) & Negative predictive value (NPV) were
calculated.
Results: Patients achieving remission tend to have lower CRP at BL,
wk4&24, compared to patients not achieving remission, and patients
treated with GLM had in general lower CRP levels than patients treated
with MTX or PBO. Changes from BL in CRP levels were analyzed in
3 RA populations and decreases from BL at wk4 in patients with
BL CRP>1 mg/dL were significantly associated with remission at
wk24 in GLMMTX patients from GO-BEFORE (OR¼ 1.4; p<0.002;
PPV¼67%; NPV¼53%), GO-FORWARD (OR¼2.1; p<0.000;
PPV¼70%; NPV¼68%) and GO-AFTER (OR¼1.3; p¼0.06;
PPV¼51%; NPV¼ 64%). Reductions from BL CRP of >50% at wk4
in these pt subsets were also significantly associated with multiple
measures of clinical response including remission.
Conclusions: While changes in CRP levels associate with clinical
response and may be a good measure of disease activity in RA at any
time point, it is not a reliable predictor of clinical response to treatment.
Disclosure statement: M.D., H.F., E.H., M.R. and S.S. are employees
of Centocor Research & Development, Inc. M.E. has received
consultancy fees from Centocor Research & Development, Inc. P.E.,
M.G. and E.M. have received research grants from Centocor Research
& Development, Inc.
188. GOLIMUMAB AND CARDIOVASCULAR DISEASE
MARKERS IN INFLAMMATORY ARTHRITIDES
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Medical Center, Dallas, TX, USA; 7Medicine, Stanford University,
Palo Alto, CA, USA; 8Rheumatology, Mayo Clinic, Rochester, MN,
USA; 9Bioinformatics, Centocor Research & Development, Inc.,
Malvern, PA, USA
Background: The purpose of this study was to assess the effect of
golimumab (GLM), a human anti-tumor necrosis factor (TNF) agent,
þ/- methotrexate (MTX), on serum lipid profiles and inflammatory
markers associated with cardiovascular disease (CVD).
Methods: Serum lipids, including LDL subfractions and inflammatory
CV markers (e.g., high sensitivity [hs]CRP, VEGF, ICAM-1, SAA,
fibrinogen, IL-6) and markers of insulin sensitivity (fasting glucose,
fasting insulin, HbA1c, HOMA-IR, QUICKI) were assessed in 2 phase 3
GLM trials in RA pts (MTX-naı¨ve in GO-BEFORE and MTX inadequate
responders [IR] in GO-FORWARD). Changes from baseline to wk14 or
24 were compared between the PBOþMTX (n¼293) and combined
GLM (50&100 mg)þMTX (n¼496) groups (grps).
Results: In GO-FORWARD, median total cholesterol (TC), high-density
lipoprotein (HDL) and low-density lipoprotein (LDL) levels increased in
the GLMþMTX compared with PBOþMTX grp (8.4 vs 1.0 mg/dL[p
0.001], 5.4 vs 0.0 mg/dL[p 0.01], 11.6 vs 3.3 mg/dL [p 0.01],
respectively), whereas atherogenic ratios (TC/HDL, LDL/HDL, Apo
B1/A1) were not substantially changed. Favourable changes in LDL
subfractions (increase in large, decrease in small LDL, increase in
mean LDL particle size) were seen in GLM grps(þ21.5 mg/dL and
-10.5 mg/dL, respectively). In GO-BEFORE, increases in TC and LDL
and favorable changes in LDL subfractions were seen in both the MTX
and GLM grps; in contrast, HDL increase and Apo B/A1 decrease were
observed in GLM but not MTX grp. Most inflammatory CV markers
improved significantly with GLMþMTX vs PBOþMTX in both studies
(hsCRP:-70.7 vs -10.4 mg/dL[p 0.001]in GO-FORWARD, -71.7 vs
-49.6 mg/dL[p 0.05]in GO-BEFORE; ICAM-1:-12.2 vs 0.0 ng/
mL[p0.001]in GO-FORWARD, -12.5 vs -0.7 ng/mL[p0.001] in
GO-BEFORE. Markers of insulin sensitivity remained unchanged at
wks14/24 in patients treated with GLM.
Conclusions: This is the first demonstration of favorable changes in
LDL subfractions with anti-TNF therapy. Despite increases in TC and
LDL, atherogenic indices remained stable and CV-related inflamma-
tory markers improved with GLM treatment. These findings are
consistent with published epidemiologic data suggesting, a beneficial
effect of anti-TNF agents on CV events. No significant changes in
insulin sensitivity parameters were observed.
Disclosure statement: J.B., R.F., M.G., B.K., E.M. and M.W. have
received research grants from Centocor Research & Development,
Inc. E.H., H.L. and M.R. are employees of Centocor Research &
Development, Inc.
189. TREATMENT WITH INFLIXIMAB IMPROVES CLINICAL
RESPONSE AND PHYSICAL FUNCTION IN PATIENTS
WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS
ACTIVELY SWITCHED FROM ETANERCEPT OR ADALIMUMAB
THERAPY
R. Fleischmann1, J. Goldman2, M. Leirisalo-Repo3, E. Zanetakis4,
H. El-Kadi5, H. Kellner6, R. Bolce7, J. Wang8, R. Dehoratius7 and
D. Decktor7
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Background: Evidence suggests that RA pts with active disease,
despite tx with SC TNFa inhibitors, respond to infliximab (IFX). The
dosing flexibility of IFX allows for the tx of continued active disease
with targeted clinical outcomes. The aim was to evaluate the safety
and efficacy of IFX in RA pts with moderate or severe RA despite tx
with etanercept (ETN) or adalimumab (ADA).
Methods: This is a Phase4, open-label, assessor-blinded,active
switch study of IFX in active RA pts who received MTX and had
inadequate response(DAS283.6, SJC6,& TJC6) to ETN or ADA.
Pts were on stable dose of MTX for 4wks prior to screening. Pts
receiving ETN were switched no less than 1wk and no more than 2wks
after the last dose; pts receiving ADA were switched no less than 2wks
and no more than 4wks after last dose. Pts received IFX 3 mg/kg
infusions at wks0, 2&6. Pts who either achieved/maintained EULAR
response at wks14 or 22 remained on current IFX dose. IFX dose was
increased by 2 mg/kg for pts who did not achieve/lost response.
EULAR response was evaluated at wk10 post induction(primary endpt)
and following incremental increases in IFX dose in pts not adequately
responding to initial doses. Physical function was assessed using
HAQ.
Results: Data for 197/203pts enrolled were evaluable. 60.9% and
39.1%pts were previously treated with ETN or ADA, respectively.
EULAR response was achieved by 49.7%pts at wk10(55.6%,per
protocol)and 51.8% at wk26(61%,per protocol) with/without dose
adjustment. Among pts responsive to 3 mg/kg induction dose, 45%
maintained response through wk26. ACR20,50&70 responses were
achieved in 28.4%,12.2% &1.5%pts at wk10, respectively; responses
improved to 35.5%, 18.3%, &7.1%, respectively, at wk26. Mean CDAI
and SDAI were 40.1 and 41.2, respectively, at baseline and
significantly improved to 21.45(p< 0.001) and 22.28(p<0.001),
respectively, at wk26. 48.3%pts previously treated with ETN and
57.1%pts previously treated with ADA achieved a EULAR response at
wk26. Changes from baseline at wks10&26 in DAS28, HAQ, SJC, and
TJC are described (Table 1). At least 1AE and serious AE were
reported in 70.4% and 4.9%pts, respectively; 6.9%pts experienced at
least 1infusion reaction (1.6%infusions were associated with an
infusion reaction).
Conclusions: RA pts actively switched from tx with ETN or ADA to
IFX, without a washout period, demonstrated a statistically significant
and clinically important improvement in EULAR response and physical
function. IFX was generally well-tolerated with no new safety signals
observed.
Disclosure statement: R.B., D.D. and R.D. are employees of
Centocor Ortho Biotech Services, LLC. H.E., R.F., J.G., H.K., M.L.
and E.Z. have received research grants from Centocor Research &
Development, Inc. J.W. is an employee of Johnson & Johnson
Pharmaceutical Research and Development, LLC.






DAS28 (ESR) 6.193 (0.981) 1.076 (1.146)* 1.468 (1.437)*
DAS28 (CRP) 5.701 (0.896) 1.088 (1.090)* 1.436 (1.312)*
HAQ improvement 1.334 (0.577) 0.173 (0.455)* 0.223 (0.497)*
SJC 17.335 (10.537) 6.960 (10.686)* 8.283 (11.380)*
TJC 30.188 (16.893) 10.460 (14.067)* 13.197 (14.304)*
*p<0.001
190. SUBCUTANEOUS GOLIMUMAB SUSTAINS EFFECTS
OF INTRAVENOUS GOLIMUMAB IN PATIENTS WITH ACTIVE
RHEUMATOID ARTHRITIS: RESULTS OF THE GO-LIVE
LONG TERM EXTENSION
J. Kremer1, Peter Taylor2, A. Mendelsohn3, D. Baker3, L. Kim3 and
C. Ritchlin on behalf of the GO-LIVE Study Group4
1Rheumatology, Albany Medical Center, Albany, NY, USA;
2Medicine, Imperial College of London, London, United Kingdom;
3Immunology, Centocor Research and Development, Inc., Malvern,
PA; 4Rheumatology, University of Rochester, Rochester, NY, USA
Background: The objective of this study was to evaluate the efficacy
and safety of SC golimumab (GLM) in RA pts who previously received
IV GLM q12 wks with and without MTX.
Methods: Adult RA pts (n¼643), with persistent disease activity while
receiving MTX>15 mg/wk for at least 3mos, were randomized to IV
placeboþMTX (n¼129) or GLM 2- or 4 mg/kg, both with and without
MTX, q12wks (n¼514) up to Wk96 [median 68.4 wks]. Pts who
received IV GLM completing the Wk48 database lock were eligible to
participate in the long term extension (LTE) and receive open label
GLM 50 mg SC q4wks for an additional 24wks (E-0 to E-24) and 16wks
of safety follow-up (E-24 to E-40) with and without MTX. At Wk E-14,
changes in concomitant RA medication (including MTX) were
permitted at the investigators discretion.
Results: Of the 505 pts who entered the LTE, 186 pts who did not
change dosing strategy during the IV phase (GLM IV 2 mg/kg IVþMTX
[n¼ 82]; GLM IV 4 mg/kgþMTX [n¼104]) participated in the LTE at
Wk E-0; baseline demographics and disease characteristics were
comparable between both groups. Through Wk E-0, ACR20, ACR50,
and DAS28-CRP (good or moderate) response was achieved by
67.5%, 61.9%, 43.4% and 39.2%, 87.7% 82.1% in the IV GLM 2 mg/
kg and 4 mg/kg groups, respectively. Overall efficacy (ACR20, ACR50)
and improvements in ACR components were sustained or improved in
a majority of pts through Wk E-24 regardless of GLM IV dose: ACR20
was achieved by 85.7% IV GLM 2 mg/kg patients and 90.8% IV GLM
4 mg/kg patients, ACR50 was achieved by 77.8% and 82.1%,
respectively. Compared with the IV phase, DAS 28 response and
CRP measures improved with SC GLM. The rates of GLM SC
discontinuations from Wk E-0 through Wk E-24 were 2.4% and
4.8% in pts previously treated with IV GLM 2- and 4 mg/kg,
respectively, most commonly for adverse events (AEs). A total of
77.5% and 83.0% of patients in the GLM IV 2- and 4mg/kg groups,
respectively, experienced >1 AEs through Wk E-0. Rates of infusion
reactions remained lower in GLM-treated pts compared with placebo-
treated pts. During the LTE (Wk E-0 through Wk E-40), 69.5% of SC
GLM-treated pts experienced >1 AE; 13.7% and 14.0% of pts
previously treated with GLM IV 2- and 4 mg/kg, respectively,
experienced >1 serious AE. Injection site reactions were rare [0.6%
(19/3443)].
Conclusions: In pts switched to SC GLM 50 mg through the LTE,
overall efficacy was sustained or improved regardless of whether pts
previously received IV GLM 2-or 4 mg/kg. Both IV and SC GLM were
well tolerated with acceptable safety profiles.
Disclosure statement: D.B., L.K. and A.M. are employees of
Centocor Research & Development, Inc. J.K., C.R. and P.T. have
received research grants from Centocor Research & Development, Inc.
191. MALIGNANCIES ASSOCIATED WITH TNF INHIBITORS
IN REGISTRIES AND PROSPECTIVE OBSERVATIONAL
STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
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Background: Tumour necrosis factor (TNF) is an important compo-
nent of host surveillance mechanisms for malignancy but also may be
involved in spread of some cancers. Patients with rheumatoid arthritis
have increased risk of lymphoma and some other cancers but a
reduced risk of colon cancer. It is important that the effect of treatment
with TNF-inhibitors (TNF-I) on cancer risk is evaluated. This project
was undertaken to assess the risk of malignancy in patients with
rheumatoid arthritis treated with TNF inhibitors in clinical practice as
recorded in prospective, observational studies.
Methods: We undertook comprehensive searches of Medline,
Embase, the Cochrane Database of Systematic Reviews and ACR,
EULAR and BSR conference abstracts according to a pre-specified
protocol. Publications that met the inclusion criteria were assessed for
quality. Data on malignancy, including type, site, percentages of
patients with malignancy, incidence rates, standardised incidence
ratios (SIR) and relative risk were extracted and meta-analyses
undertaken.
Results: The searches identified totals of 2039 papers and 1979
abstracts of which 20 full-texts and 7 conference abstracts met the
inclusion criteria. Six studies contained sufficient data on malignancy
to be included in the meta-analysis. The pooled estimate was 0.91
(95% CI 0.82, 1.01) indicating that treatment with TNF-I was not
associated with an overall increased risk of malignancy compared with
non-exposed RA patients. There was no evidence that longer duration
of exposure increased the risk of malignancy nor that prior malignancy
increased the relative risk, although the absolute rates of malignancy in
both exposed and non-exposed patients was higher than in patients
without a prior history of cancer.
Comparisons of incidence ratios of lymphoma in exposed and non-
exposed patients were reported in three studies. The pooled estimate
was 1.11 (95% CI 0.70, 1.61). Results from four studies showed that
patients treated with TNF-I have a significantly increased risk of
developing an NMSC (1.45; 95% CI 1.15, 1.85). Additionally, patients
may be at an increased risk of developing melanoma, as the pooled
estimate, that included two studies, was 1.79 (95% CI 0.92, 2.89).
Conclusions: This systematic review and meta-analysis provides
reassurance to physicians and patients that treatment of RA patients
with TNF-I does not increase the risk of malignancy in general or of
lymphoma in particular but does appear to increase the risk of skin
cancer, including melanoma. The confidence intervals however do not
preclude an effect of treatment on risk of malignancy and researchers
should be encouraged to publish additional analyses to add to the
evidence base.
Disclosure statement: P.E. has received research grants and
honoraria from Abbott, Bristol-Myers Squibb, Pfizer, Roche,
Schering-Plough and UCB. R.H. and R.L. have received research
grants from Pfizer. X.M. has received honoraria for talks and advisory
boards from Pfizer, Roche and UCB. M.M. has received lecture fees
from Actelion, Bristol-Myers Squibb, Roche and Pfizer, and research
grants from Actelion, Pfizer, Centocor and Schering-Plough. K.P. has
received consultancy fees from Abbott, Pfizer, Roche and Schering-
Plough. A.R. has received consultancy fees from Napp, and is a
previous employee of, holds share options with, and has received
consultancy fees from Pfizer. P.T. has received lecture and con-
sultancy fees from Abbott, Bristol-Myers Squibb, Centocor, Pfizer,
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and Glaxo Smith Kline. R.V. has received research grants and
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192. SELECTION OF NON-BIOLOGIC DISEASE-MODIFYING
ANTIRHEUMATIC DRUGS DEPENDING ON CLINICAL,
LABORATORY AND RADIOLOGICAL CHARACTERISTICS
OF RHEUMATOID ARTHRITIS
Oleg Iaremenko1 and Ganna Mikitenko1
1Internal Medicine N2, National Medical University O.O.Bogomolets,
Kyiv, Ukraine
Background: it has now been well established that early treatment of
RA with DMARDs should be initiated to control the inflammatory
activity and slow the structural damage. Unfortunately, very little
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information is available on the efficacy of DMARDs depending on
clinical, laboratory and radiological characteristics of RA.
Methods: 402 pts with RA (45.4% with early RA, including 11.9% pts
with very early RA) were studied. Average age at inclusion was
50.40.63 yrs, mean disease duration - 51.5 3.31 mth. 78.9% of the
pts were women; 62.6% were positive for rheumatoid factor (RF) and
75.7% - for antibodies against cyclic citrullinated peptides (anti-CCP
AB). Outcomes after 2 yrs treatment were assessed by disease activity
score (DAS28) and X-ray changes (modified Sharp-van der Heijde
scoring method). Using the stepwise multiple logistic regression
analysis, the most important prognostic factors of RA progression
were found. Analysis of treatment efficacy depending on the duration,
clinical (presence of extraarticular manifestations /EAM/), laboratory
(RF, anti-CCP AB, elevated C-reactive protein (CRP) level) and X-ray
(presence of erosive changes) characteristics, disease activity of RA
was performed.
Results: in 24 months, ACR20% response rate with MTX in low and
medium doses was similar (43.8% vs 53.7%, p> 0.05), but MTX in
medium doses was better than MTX in low doses in ACR50/70%
response rates (29.8/8.77% vs 13.4/1.81%, p<0.01). Remission was
achieved more often in pts received medium doses of MTX then low
doses (12.4% vs 3.63%, p<0.05). X-ray changes after 2 yrs were
more than twice as apparent in group with low doses of MTX. For the
following analysis only pts received medium doses of MTX was
included. By the results of the stepwise multiple logistic regression
analysis the most important prognostic factors of RA progression are
presence of anti-CCP AB (B¼12.8, p<0.001), the basic change in the
total X-ray score (B¼ 6.7, p< 0.001) and presence of RF (B¼3.3,
p<0.001). The other factors (titer of RF, presence of EAM, level of
anti-CCP and CRP, basic disease activity) had significant but less
essential impact on RA progression.
Conclusions: anti-CCP AB must be measured even in RF(þ ) pts as
the most significant prognostic factor of RA progression. SS can be
prescribed for pts with low disease activity; for pts with higher activity
but RF(-), anti-CCP(-) RA, without EAM and erosive RA. LF is better for
early and late anti-CCP(þ ) RA, including pts with high CRP level. MTX
(15 mg/w) can be prescribed for all pts except pts with early and late
anti-CCP(þ) RA. In case of ineffectiveness of MTX or LF for pts with
moderate or high activity, CBT must be prescribed: for very early anti-
CCP(þ) RA with high CRP level; for early anti-CCP(þ) RA despite of
CRP level; for all pts with late RA except for non-erosive pts.
Disclosure statement: The authors have declared no conflicts of
interest.
193. EFFICACY SUSTAINED AFTER DOSE DE-ESCALATION
OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS
PATIENTS: POST-HOC ANALYSIS OF THE RAPID 2
OPEN-LABEL EXTENSION
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Background: In the RAPID studies, certolizumab pegol (CZP) 200 mg
or 400 mg every other week (EOW)þmethotrexate (MTX) was
efficacious and well tolerated in patients (pts) with active rheumatoid
arthritis (RA); the 2 CZP doses showed similar efficacy and safety (CZP
400 mg EOW is not licensed in the UK). Pts who completed these
studies (completers) were eligible to enter open-label (OL) extensions
(OLE) of CZP 400 mg EOWþMTX. Increasing the CZP dose from 200
to 400 mg EOW upon OLE entry in CZP 200-mg completers did not, on
average, provide additional efficacy benefit compared with pts treated
with CZP 400 mg throughout. Pts have now been followed to 3 years
(yrs) (148 weeks [wks]) from the RAPID 2 baseline, during which time
the CZP dose was decreased from 400 to 200 mg EOW per protocol
(after 6 months in the OLE) in some pts. The purpose of this analysis
is to investigate the impact of CZP dose decrease on efficacy in RA
pts.
Methods: This analysis includes all RAPID 2 CZP 200- and 400-mg
completers who received CZP 400 mg EOWþMTX in the OLE and
who subsequently had the CZP dose decreased to 200 mg EOW by
the 3-yr data cut. CZP dose decrease was mandatory after 6 months
in the OLE. As the dose decrease in pts occurred at different times,
data are shown up to 48 wks of CZP exposure following dose
decrease, with Wk 0 (for this analysis) set as the last efficacy
assessment visit prior to dose decrease; CZP dose decrease occurred
between Wks 0 and 10. Wk 12 is therefore the first visit after dose
decrease. Analyses include mean DAS28 (ESR) and HAQ-DI
scores (last observation carried forward [LOCF]) and ACR responses
(non-responder imputation). Data are shown by treatment originally
received in RAPID 2 (200 or 400 mg EOWþMTX). RAPID 2:
NCT00160602; RAPID 2 OLE: NCT00160641.
Results: Of 342 RAPID 2 completers who received OL CZP
400 mgþMTX, the CZP dose was decreased in 287 (139 CZP 200-
mg and 148 CZP 400-mg completers) by the 3-yr data cut. All 287 pts
received OL CZP 400 mg for1 yr prior to dose decrease, with 126
and 132 CZP 200- and 400-mg completers, respectively, having
reached up to 48 wks exposure following dose decrease (Wk 48 of this
analysis). Mean DAS28 scores were 3.77 (SD: 1.22) and 3.54 (1.08) in
CZP 200- and 400-mg completers at Wk 0 and remained similar after
dose decrease to Wk 48. Mean HAQ-DI scores were 0.91 (0.61) and
0.90 (0.56) in CZP 200-mg and 400-mg completers, respectively, at
Wk 0 and were similar to Wk 48 (0.87 [0.59] and 0.84 [0.56],
respectively). The ACR50 response rates at Wk 48 after dose-
decrease were 47% and 42% for CZP 200-mg and 400-mg
completers, respectively; the ACR70 response rates were 24% and
22%, respectively.
Conclusions: In RA pts who had an initial response to CZP, efficacy
was maintained in the OLE after CZP dose decrease from 400 mg to
200 mg EOWþMTX.
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Background: The relationship between an early response to biologic
therapy and longer-term clinical outcomes has not been well
characterized. We conducted a post hoc analysis to determine the
relationship between initial improvement in DAS28(ESR) score within
12 weeks (wks) and probability of achieving low disease activity (LDA;
DAS28 3.2) at Wk 52 in RA patients (pts) treated with CZP.
Methods: The proportion of pts treated with CZP (200 or
400 mg*)þMTX who had LDA at Wk 52 was assessed among pts
who achieved or failed to achieve various DAS28 responses (ie, DAS28
decrease from baseline [BL] <0.3, 0.6, 0.9, 1.2, 1.5 and 1.8 units) by
Wks 1, 2, 4, 6, 8, 10, or 12. The results were analyzed for the ITT
(LOCF) population. Pts
with nonimputable missing data during the first 12 wks of treatment
were excluded from the analysis. *CZP 400 mg every other week is not
licensed in the UK.
Results: Of the 783 pts randomized to CZPþMTX, 98% had
DAS28> 5.1 at BL; 30% achieved LDA by Wk 52. By Wk 12, 98%,
87%, and 74% of CZP-treated pts had DAS28 decreases from
BL 0.3, 1.2, and 1.8, respectively. CZP-treated pts who improved
their DAS from BL by< 0.3 up to Wk 6 (N¼41) had 0% probability of
achieving LDA at Wk 52 (Table 1). Similarly, pts who improved their
DAS from BL by <0.6 or 0.9 up to Wk 10 (N¼45 and N¼ 76,
respectively) had 0% chance to achieve LDA at Wk 52. Pts who had a
change of <0.3 at Wk 4, <0.6 and 0.9 at Wk 6, <1.2 at Wk 8, or <1.5
and 1.8 at Wk 12 had a <5% probability of achieving LDA at Wk 52
(bolded rows of Table 1).
Conclusions: Long-term response to CZP can be estimated early in
the course of treatment. The majority of RA pts respond within the first
12 wks of CZP treatment. Furthermore, the probability of not achieving
LDA at Wk 52 can be predicted by a combination of the change in
DAS28 from BL and the time at which DAS28 was assessed after
starting CZP treatment.
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Background: Normal fluctuations in disease activity measurements
due to short-term situational effects and measurement errors
complicate the evaluation of a clinically meaningful therapeutic
response. We have addressed this difficulty by using a statistical
approach to determine a critical difference (dcrit) that defines valid
criterion for response as assessed by the Disease Activity Score-28
joints (DAS28).
Methods: The reference population was derived from two clinics and
consisted of 101 RA patients with stable responses to DMARD or
biologic therapy. Therapy was not changed in these patients and their
disease course remained stable from months 12 to 24 after therapy
initiation. To evaluate changes in DAS28 scores, we subjected
patients’ DAS28 scores at 12, 18, and 24 months to an ANOVA
model to establish a 95% one sided confidence interval (95% CI) for
normal fluctuations; this value was used to define the dcrit for
individual changes. DAS28 changes less than the dcrit value
represented the normal variation in DAS28 scores during stable
disease and stable treatment, while changes that were equal to or
greater than the dcrit can be considered to represent a therapeutic
response.
Results: The overall dcrit value in the 101-patient reference population
was 1.70. Values for dcrit were comparable regardless of treatment
center, class of therapy (DMARDs or biologics), or baseline disease
activity (Table 1). Male patients had a lower dcrit value than female
patients, possibly due to the relatively small number of males in this
population. In all subgroups except one, the dcrit value fell below 1.8.
We thus conclude that DAS28 improvements of 1.8 or higher are
outside the normal variation and represent a real therapeutic response.
Conclusions: Based on our data, a dcrit value of 1.8 (DAS28
improvement of 1.8 points) signifies a positive individual therapeutic
response that exceeds the threshold of random fluctuation. The dcrit
value determined by statistical analysis of normal variation in DAS28
scores is higher than the DAS28 change required to achieve a good
EULAR response (1.2 points) and is independent of baseline disease
activity, which may make it more convenient for clinical use. Further
studies in larger populations will be required to confirm the utility of the
dcrit value in determining therapeutic response. However, preliminary
data suggest that a dcrit value of 1.8 has the potential to guide
treatment decisions in daily clinical practice and to facilitate research
on treatment responders.
Disclosure statement: F.B., H.B. and H.T. have received research
grants from Abbott. G.W. has received honoraria from Abbott. All other
authors have declared no conflicts of interest.
TABLE 1. dcrit value (DAS28 decrease) in patients subgroups








DMARDs Biologic DAS< 3.2 DAS> 3.2 Male Female
n¼ 51 n¼ 50 n¼ 41 n¼ 60 n¼ 76 n¼ 25 n¼ 22 n¼ 79
1.71 1.69 1.83 1.61 1.50 1.79 1.39 1.78
196. A COMPARISON OF THE USE OF ANTI-TNFa
AGENTS BEFORE AND AFTER A DECISION TO USE TRIPLE
COMBINATION THERAPY AT BASELINE IN EARLY RA
Karina J. Blunn1, Richard B. Williams1, Adam Young2 and
Jackie McDowell1
1Rheumatology, Hereford Hospitals NHS Trust, Hereford,
United Kingdom; 2Rheumatology, St Albans NHS Trust, Herts,
United Kingdom
Background: The Early Rheumatoid Arthritis Network (ERAN)is an
observational study of the secondary care management of early RA in
the UK and Eire. The decision to use combination therapy for early RA
was made in Oct 2006 in Hereford.This has since been demonstrated
as feasible in real life clinical practice and as making a statistically
significant difference in outcome in Hereford. Objective: To explore
any differences in the use of Anti-TNFa agents before and after the
decision to use combination therapy as standard first line treatment
in early RA
Methods: Since October 2006 a combination of Methotrexate (MTX),
Sulfasalazine (SSZ) and Hydroxychloroquine (HCQ) has been offered
to the majority of patients with early RA and is started within 3 months
of a decision to treat, usually at the time of diagnosis.This is escalated
to maximum tolerated doses within 3 months.Patients failing to
respond are offered either an alternative DMARD or a biologic agent
depending on clinical assessment and NICE recommendations for
the use of biologics. Standardised data comparable with that collected
for the BSR biologics registry including details of drug therapy and
rationale for discontinuation has been collected and has been
analysed using the ERAN database. This data has been verified with
the case notes by an external monitor. The cohort has been divided
into groups A and B; pre and post decision to use combination therapy
as standard respectively.
Results: Baseline demographics are similar across the two groups.
Data is available on 231 participants at baseline.Group A pre decision
to use combination therapy as standard mean age 57, Female 65.1%,
erosions 20.5% 63.7% sero-positive. Group B post decision to use
combination therapy as standard mean age 61. Female:65.7%,
erosions:21.5%, 65% sero positive.Analysis using Pearson Chi-
Square tests show no statistically significant difference in the use of
anti-TNFa agents between the two groups.
Conclusions: There is no change in the percentage of patients treated
with biologics since the introduction of aggressive combination
therapy for RA in the first 3 years from diagnosis. The use of com-
bination therapy in early RA is part of a strategy of tight disease
control. It was expected to rapidly define a population of refractory RA
patients eligible for biologic therapy, and therefore to increase the use
of biologics. These data do not support this hypothesis.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Percentagea of CZP-treated patients with LDA at Week 52 out of those who failed to achieve DAS decreases up to week of follow-up for the first 12 weeks
DAS28 Change Week
1 2 4 6 8 10 12
<0.3 19.5 (N¼ 220) 11.6 (N¼112) 3.2 (N¼63) 0 (N¼ 41) 0 (N¼27) 0 (N¼ 19) 0 (N¼ 14)
<0.6 21.0 (N¼ 352) 14.8 (N¼209) 7.1 (N¼ 126) 2.5 (N¼ 79) 3.2 (N¼ 63) 0 (N¼ 45) 0 (N¼ 34)
<0.9 22.8 (N¼ 457) 17.0 (N¼317) 8.9 (N¼ 202) 4.2 (N¼ 144) 2.8 (N¼ 106) 0 (N¼ 76) 0 (N¼ 67)
<1.2 24.7 (N¼ 546) 19.1 (N¼418) 12.8 (N¼ 288) 7.5 (N¼ 214) 4.5 (N¼ 157) 3.1 (N¼129) 1.0 (N¼ 103)
<1.5 26.1 (N¼ 605) 21.5 (N¼492) 16.5 (N¼ 369) 11.7 (N¼ 281) 7.2 (N¼ 221) 5.5 (N¼ 182) 2.1 (N¼ 145)
<1.8 27.9 (N¼ 656) 24.4 (N¼573) 17.4 (N¼ 448) 12.3 (N¼ 357) 9.5 (N¼ 294) 7.3 (N¼ 245) 4.9 (N¼ 206)
aN numbers are denominators for % calculations and are the number of patients not achieving the DAS28 change threshold at the week presented.
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TABLE 1.
Year Drugs GROUP A GROUP B
1 Total n¼ 117 Total n¼ 61
combination 9% 64%
anti-TNF 3% 5%
2 Total n¼ 108 Total n¼ 29
Combination 9% 65%
Anti-TNF 7% 7%
3 Total n¼ 104 Total n¼ 6
combination 8% 83%
Anti-TNF 15% 17%
197. CLINICAL AND RADIOGRAPHIC IMPLICATIONS
OF TIME TO TREATMENT RESPONSE IN PATIENTS WITH
EARLY RHEUMATOID ARTHRITIS
Edward Keystone1, Michael Weinblatt2, Boulos Haraoui3,
Benoit Gue´rette4, Neelufar Mozaffarian5, Kaushik Patra5 and
Arthur Kavanaugh6
1The Rebecca MacDonald Centre for Arthritis and Autoimmune
Disease, Mount Sinai Hospital, University of Toronto, Toronto, ON,
Canada; 2Medicine: Rheumatology, Immunology and Allergy,
Brigham and Women’s Hospital, Boston, MA, USA; 3Medicine:
Rheumatology, Centre Hospitalier de I’Universite´ de Montre´al
(CHUM, Hoˆpital Notre-Dame), Montre´al, QC, Canada; 4Global
Pharmaceutical Research and Development, Abbott, Rungis, France;
5Global Pharmaceutical Research and Development, Abbott, Abbott
Park, IL, USA; 6Center for Innovative Therapy, Division of
Rheumatology, Allergy, and Immunology, University of California
at San Diego, San Diego, CA, USA
Background: Recent publications advocate treatment adjustment at
12 weeks for patients with rheumatoid arthritis (RA); still, data support
the possibility of later responses to therapy. Our objective was to
evaluate the association of early (12 weeks) and delayed (24 weeks)
clinical responses with rates of clinical remission, low-disease activity
(LDAS), and rapid radiographic progression (RRP) at 52 weeks in
patients with early RA treated with MTX monotherapy or adalimumab
(ADA)þMTX combination therapy in the PREMIER trial.
Methods: PREMIER was a 104-week, phase 3, randomized, placebo-
controlled trial in a MTX-naı¨ve population with early RA. In this post
hoc analysis, observed data comparing MTX with ADA þ MTX therapy
are presented. Clinical outcome measures included the 28-joint
Disease Activity Score (DAS28) and mean change from baseline in
modified Total Sharp Score (mTSS) at 52 weeks. Patients were
categorized on the basis of clinical response (DAS28 improvement
>1.2 or 20/50/70% improvement in ACR score) at 12 and 24 weeks:
‘‘early responders’’ achieved the clinical target at week 12 and
maintained the response at week 24; ‘‘delayed responders’’ did not
meet the clinical target until week 24. The percentages of patients at
52 weeks with LDAS (DAS28 <3.2), clinical remission (DAS28 <2.6),
and RRP (mTSS >3 units/year) in each group were determined.
Results: In both treatment groups, early clinical responses were
associated with better long-term outcomes than delayed responses.
Achieving early or delayed ACR70 responses did not result in
treatment group differences in the proportion of patients achieving
LDAS or clinical remission at week 52. However, delayed responses to
MTX resulted in a high proportion of patients with RRP. Indeed,
delayed ACR70 responses were associated with an RRP prevalence of
40%. In addition, even an early improvement of DAS28 >1.2 with MTX
was insufficient to slow radiographic progression (41% RRP). In
contrast, early or delayed clinical responses to ADAþMTX resulted in
low proportions of RRP at 52 weeks, even for patients with a delayed
ACR20 response (11% RRP). Of note, ADAþMTX delayed responders
had less RRP than MTX-treated early responders.
Conclusions: MTX-treated patients with early RA who fail to achieve
an ACR70 within 12 wks of treatment are at risk for RRP and should be
considered for treatment adjustment. In contrast, ADAþMTX treat-
ment is associated with better clinical outcomes and less severe
radiographic progression at 52 wks, even among patients with a
delayed clinical response.
Disclosure statement: B.G., N.M. and K.P. are full-time employees of
and may hold stock or stock options with Abbott. A.K. conducted
research studies on behalf of Abbott. E.K. has received consultancy
fees or other remuneration from Abbott, UCB, Pfizer, Roche, Amgen
and Bristol-Myers Squibb. M.W. has received research grants,
consultancy fees or other remuneration from Abbott, and consultancy
fees or other remuneration from Amgen, Pfizer, Centocor, UCB, Roche
and Bristol-Myers Squibb. All other authors have declared no conflicts
of interest.
198. 4.2-YEAR RESULTS: LONG-TERM EFFICACY OF
TOCILIZUMAB TREATMENT FOR RA
Majed Khraishi1, Rieke Alten2, Juan Gomez-Reino3, Warren Rizzo4,
Joy Schechtman5, Andre Kahan6, Emma Vernon7, Monet Taylor7 and
Josef Smolen8
1Rheumatology, Memorial University of Newfoundland, St Johns,
Canada; 2Rheumatology, University of Berlin, Berlin, Germany;
3Rheumatology, Hospital Clı´nico U. de Santiago, Santiago, Spain;
4Rheumatology, Advance Arthritis care, Scottsdale, AZ, USA;
5Rheumatology, Sun Valley Arthritis Center, Peoria, AZ, USA;
6Rheumatology, Paris Descartes University, Paris, France;
7Rheumatology, Roche, Welwyn, United Kingdom; 8Rheumatology,
University Clinic for Internal Medicine, Vienna, Austria
Background: Randomised Phase III trials have demonstrated the
efficacy and safety of tocilizumab (TCZ) in patients with RA. The
majority of patients continued therapy in the long-term extension
studies (GROWTH95, GROWTH96, open-label phase of LITHE) and
data from 2904 patients with moderate-to-severe RA and an
inadequate response to DMARDS (DMARD-IR patients) treated with
TCZ plus DMARDS for up to 4.2 years are presented here.
Methods: Patients were assessed every 4 weeks in the original studies
and every 8 or 12 weeks in the extension studies, from first dose to 28
August 2009. Data were assigned to the nearest 12-week point. There
was no imputation of missing data.
Results: TCZ increased absolute numbers of DMARD-IR patients
achieving ACR50, LDA and DAS28 remission through Week 96 and
ACR70 through Week 120. However, these data must be interpreted
with caution due to lower absolute numbers over time. ACR70
response rates were maintained for 24 consecutive weeks by Week
144 in 20% of assessed DMARD-IR patients. At Week 120, 52.3%
of assessed patients had 1 swollen joint count and 38.4% had 1
tender joint count. HAQ scores of 0.5 were achieved in 38.4% of
patients.
Conclusions: Efficacy during long-term TCZ treatment was demon-
strated by increasing patient numbers achieving ACR50/70 and LDA/
DAS28, maintained over time. These data support TCZ as an effective,
long-term treatment for DMARD-IR RA patients.
199. CHANGES IN GENE EXPRESSION IN SYNOVIAL TISSUE
FROM REFRACTORY RHEUMATOID ARTHRITIS PATIENTS
TREATED WITH RITUXIMAB
Vanessa Hogan1, Cecile Holweg2, Sarah Kummerfeld2, Onno Teng3,
Michael Townsend2 and Jacob M. van Laar1
1Musculoskeletal Research Group, Newcastle University, Newcastle
Upon Tyne, United Kingdom; 2gRED Biomarker Group, Genentech,
Palo Alto, CA, USA; 3Rheumatology, Leiden University Medical
Centre, Leiden, Netherlands
Background: To determine the effects of the B cell depleting drug
rituximab on gene expression in synovial tissue from patients with
TABLE 1. Long-term efficacy of TCZ in DMARD-IR patients
Week 0 24 48 72 96 120 144 168 192
ACR50 35 45 50 53 56 56 61 66
929/2693 1088/2439 1162/2312 1183/2227 1154/2047 1028/1825 802/1323 469/716
ACR70 16 24 30 31 35 35 43 45
423/2693 581/2439 692/2312 698/2227 714/2047 638/1825 562/1323 325/716
LDA 2 43 54 62 65 68 69 70 73
50/2889 1137/2658 1302/2396 1403/2261 1409/2158 1352/1978 1208/1755 887/1268 500/689
DAS28 1 27 40 47 50 54 54 57 61
remission 22/2889 722/2658 962/2396 1066/2261 1083/2158 1061/1978 951/1755 718/1268 420/689
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refractory rheumatoid arthritis (RA) who have been on rituximab for
2 years.
Methods: Synovial tissue biopsies were collected from 19 patients
with refractory rheumatoid arthritis at baseline, and 3 months after the
first infusion of rituximab. 117 genes of interest were selected for
analysis, including immune cell genes and fibrosis genes. Analysis was
carried out using microfluidic real-time q-PCR and CT values were
then obtained using the fluidigm gene expression data analysis
software (version 2.1.1 Fluidigm Corporation).
Results: B cell depletion was evident in both responders and non
responders of rituximab between baseline and 3 months as assessed
by CD19 and CD20 gene expression. A number of genes were
differentially expressed in responders compared to non responders of
rituximab at baseline. An unsupervised hierarchical cluster analysis
revealed the presence of two groups of RA patients. One with high
inflammation at baseline and one with low inflammation at baseline.
The high inflammation group had significantly higher DAS28, higher
erythrocyte sedimentation rate, higher C-reactive protein levels and a
greater change in DAS28 over 3 months.
Conclusions: These results show the existence of two distinct RA
patient subgroups, where high inflammation tissue is associated with
more severe disease and a better response to rituximab.
Disclosure statement: J.vL. did the gene expression analysis in
collaboration with Roche. All other authors have declared no conflicts
of interest.
200. SWITCHING BETWEEN BIOLOGIC THERAPIES
IN CLINICAL PRACTICE
Nicola J. Gullick1,2, Chulanie De Silva1 and Bruce W. Kirkham1,2
1Rheumatology, Guy’s & St Thomas’ NHS Foundation Trust, London,
United Kingdom; 2NIHR Comprehensive Biomedical Research
Centre, Guy’s & St Thomas’ Hospitals & King’s College London,
London, United Kingdom
Background: Treatment with Tumour necrosis factor-alpha inhibitors
(TNFi) is standard therapy for patients with severe rheumatoid arthritis
(RA) despite conventional DMARDs. Significant numbers of patients
do not respond or experience adverse events to TNFi. We explored the
hypothesis that patients who do not initially respond to TNFi (primary
failure) respond less well to subsequent TNFi therapy than those
switching for secondary failure or adverse events.
Methods: Patients with RA who had received TNFi prior to March
2010 were identified from existing databases. Medical notes were
reviewed for all those with available 6 month follow up data. Changes
in DAS28, ESR, CRP, EULAR responses were recorded, as well as
reasons for discontinuation and response to subsequent therapy.
Results: 297 patients were identified. 248 (83%) patients were female.
Patients had active (median DAS28 5.9; IQR 1.1) longstanding (median
13, IQR 14 years) disease, most were seropositive and erosive (78%).
146 (69%) were on methotrexate (median dose 21 mg/wk, IQR 10 mg)
and had taken median 3 DMARDs previously (IQR 1). Good or
moderate EULAR responses were seen in 219 patients (74%). 51
patients (17%) did not respond, and 27 patients experienced early
adverse events. 74 patients deteriorated (secondary failure) after
median 18 (IQR 12) months. 19 patients experienced late adverse
events leading to a change in therapy. Patients discontinuing their
initial TNFi had higher disease duration at baseline (median 14 vs. 12
p¼0.03), but there were no other differences in baseline character-
istics. 158 patients switched to other TNFi, and had available response
data at 6 months. 102 patients (65%) had good or moderate responses
to their next drug, and there was no increase in adverse events
(19%, 30 patients). However, 53 patients (34%) did not respond to
their second drug. Successful treatment was less common if the first
drug had been stopped due to primary failure (34% good/moderate
responses, p<0.0001 vs. switching for adverse event or secondary
failure). Conversely, 85% patients with an adverse event to the first
drug responded to the second, and 75% responded after switching
because of secondary failure. There were no differences in response if
there was a change from an antibody to a receptor construct or
between two different antibodies (e.g. IFX to ADA).
Conclusions: We report high initial response rates to TNFi therapy,
but many patients are unable to continue therapy long term. The most
common reason for discontinuation was secondary failure, which may
be due to development of antibodies specific to a TNFi. Current NICE
guidelines state that these patients should be treated with rituximab.
We suggest that patients who fail their initial TNFi course because of
adverse events or secondary failure should receive a second TNFi.
Response rates after primary failure of TNFi were poor in our cohort
supporting the use of therapies with an alternative mode of action in
this group.
Disclosure statement: B.K. has participated in advisory boards for
Pfizer, Centocor, Abbott, Bristol-Myers Squibb, Roche and UCB, and
has received research grants from Pfizer, Centocor and Abbott.
All other authors have declared no conflicts of interest.
201. JOINT SPACE NARROWING HAS A STRONGER IMPACT
ON PHYSICAL FUNCTION THAN JOINT EROSION: RESULTS
FROM EIGHT YEAR LONGITUDINAL ANALYSES
De´sire´e van der Heijde1, Robert Landewe2, Benoit Gue´rette3,
Sanjoy Roy4, Kaushik Patra4 and Edward Keystone5
1Department of Rheumatology, Leiden University Medical Center,
Leiden, Netherlands; 2Department of Internal Medicine/
Rheumatology, University Hospital Maastricht, Maastricht,
Netherlands; 3Global Pharmaceutical Research and Development,
Abbott, Rungis, France; 4Global Pharmaceutical Research and
Development, Abbott, Abbott Park, IL, USA; 5The Rebecca
MacDonald Centre for Arthritis and Autoimmune Disease, Mount
Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background: Structural damage, assessed by the modified Total
Sharp Score (mTSS), has been shown to be related to physical
function. Thus far, it remains unclear to what extent the individual
components of the mTSS contribute to long-term physical function.
The objective of this analysis was to characterize the longitudinal
relationship between physical function and Joint Space Narrowing
(JSN) or Joint Erosion (JE) in patients with advanced RA.
Methods: DE019 was a 52-week, phase 3, randomized, placebo-
controlled trial for the treatment of moderate to severe advanced RA,
in which patients with an inadequate response to methotrexate (MTX)
were randomized to weekly placebo, weekly adalimumab (ADA) 20 mg,
or ADA 40 mg every other week (eow), alongside concomitant MTX
therapy. Patients completing the double-blind study were eligible to
receive open-label ADA 40 mg eowþMTX for an additional 7 years.
This post hoc analysis evaluated the 8-year completers cohort with
radiographs available at baseline and years 5, 6, and 8. 28-joint
Disease Activity Score (DAS28) was used to assess clinical levels of
disease activity. Physical function was assessed through the Health
Assessment Questionnaire (HAQ). Radiographic damage was
assessed using the modified Total Sharp Score (mTSS). Longitudinal
generalized linear modeling was used to characterize the dependence
of the HAQ on concurrent DAS28, total mTSS, JSN, and JE values,
following adjustment for baseline age and gender and for concurrent
CRP.
Results: Over time, DAS28 was linearly associated with the HAQ
(P<0.001). Similarly, the mTSS was significantly associated with the
HAQ throughout treatment duration (P <0.001). A 1 unit increase in
DAS28 and a 20 unit increase in mTSS were associated with 0.22 and
0.044 increases in the HAQ, respectively. A breakdown of mTSS into
the individual components revealed that JSN more strongly impacted
the HAQ over time than JE, although both were significant determi-
nants (P< 0.001 for both). A 20 unit increase in JSN and JE were
associated with 0.1 and 0.06 increases in the HAQ, respectively.
Interestingly, negative changes in mTSS trended towards lower HAQ
values over time.
Conclusions: For patients with advanced disease, long-term physical
functioning is associated with both the level of disease activity (DAS28)
and the extent of radiographic damage (mTSS). Of the contributors
to the mTSS, JSN had a greater impact on the HAQ over time than JE,
suggesting that therapies with high potency for inhibiting both the
progression of JSN and JE should be considered.
Disclosure statement: B.G. is a full-time employee of Abbott and may
hold Abbott stock or stock options. E.K. has received consultancy fees
or other remuneration from Abbott, Amgen, Bristol-Myers Squibb,
UCB, Pfizer and Roche. R.L. has received research grants, con-
sultancy fees or other remuneration from, and is/has been a member
of speakers’ bureaus for Abbott, Amgen, Centocor, Pfizer/Wyeth, UCB
and Bristol-Myers Squibb. K.P. and S.R. are full-time employees of
Abbott and may hold Abbott stock or stock options. D.V. has received
consultancy fees or other remuneration from Abbott, Amgen, Bristol-
Myers Squibb, Centocor, Chugai, Merck, Novartis, Pfizer, Roche,
Sanofi-Aventis, Schering-Plough, UCB and Wyeth.
202. GOLIMUMAB AND RADIOGRAPHIC PROGRESSION
IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE
AND GO-FORWARD STUDIES
P. Emery1, R. Fleischmann2, D. van der Heijde3, E. Keystone4,
M. C. Genovese5, P. G. Conaghan6, E. C. Hsia7,8, W. Xu9,
A. Baratelle7, A. Beutler7 and M. U. Rahman (for GO-BEFORE &
GO-FORWARD Investigators)7,8
Poster Viewing III Thursday 14 April 2011, 09:15–10:45 iii119
1Rheumatology, University of Leeds, Leeds, United Kingdom;
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University of Leeds, Leeds, United Kingdom; 7Immunology, Centocor
Research & Development, Inc., Malvern, PA, USA; 8Rheumatology,
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Malvern, PA, USA
Background: The objective of this study was to evaluate the effect
of golimumab (GLM) on radiographic progression in pts with RA.
Methods: In both GO-BEFORE (MTX-naı¨ve pts; n¼ 637) and GO-
FORWARD (MTX-inadequately responding (IR) pts; n¼444) pts were
randomized to PBOþMTX, GLM 100 mgþPBO, GLM 50 mgþMTX,
or GLM 100 mgþMTX. Subcutaneous injections were administered q4
wks. GO-BEFORE had a control period of 52wks with early escape
[EE] at wk 28 and GO-FORWARD had a control period of 24wks with
EE at wk16. Pts in control grps meeting EE criteria start receiving GLM
50 mgþMTX. Radiographs of hands and feet at baseline, wk24 (wk16
for EE pts) and wk52 in GO-FORWARD, and baseline, wk 28, and wk
52 in GO-BEFORE were scored by 2 independent readers and an
adjudicator using the van der Heijde -Sharp score (vdHS). Different
readers were used for the two trials. Linear extrapolation was used for
radiographs taken at EE visits.
Results: In the MTX-naı¨ve population, mean vdHS changes (SD)
from baseline to wk52 (co-primary endpoint) in both the 50 mg
and 100 mg GLMþMTX grps were significantly lower compared with
those in the PBOþMTX grp (0.74 5.23[p¼0.015] and 0.07 1.83
[p¼0.025] versus 1.37 4.56, respectively, in GO-BEFORE;
0.934.86[p¼0.855] and 0.151.64[p¼ 0.221] versus 1.104.68,
respectively, in GO-FORWARD). In the MTX-IR population, vdHS
changes from baseline to wk 24 (primary analysis) were minimal in all
grps, preventing any significant effect of GLM to be detected. The
proportion of pts with change in vdHS above the smallest detectable
change (SDC¼2.58 for the study) was 4 % in the PBOþMTX group.
The lack of progression in the PBO grp may have been due to the short
PBO-control period (in PBOþMTX grp 32% EE at wk16 and remaining
pts crossed over at wk 24 to receive GLM) and relatively less active pt
population (median CRP of 0.9, lower joint counts, lower baseline
vdHS scores) than in previously reported trials in similar populations.
Conclusions: Both GLM 50þMTX & GLM100 mgþMTX demon-
strated statistically significant and comparable inhibition of radio-
graphic progression in MTX-naı¨ve population compared with MTX
alone. In the MTX-IR population the minimal radiographic progression
in the MTX alone grp prevented any effect of GLM to be detected.
Disclosure statement: A.Ba., A.Be., E.H., M.R. and W.X. are
employees of Centocor Research & Development, Inc. P.C., P.E.,
R.F., M.G., E.K. and D.V. have received research grants from Centocor
Research & Development, Inc.
203. HOW MANY PATIENTS WITH RHEUMATOID ARTHRITIS
START AND REMAIN ON DMARD MONOTHERAPY OVER
THREE YEARS AND WHAT IS THEIR OUTCOME?
Elena Nikiphorou1, Patrick Kiely2, David A. Walsh3, Richard Williams4
and Adam Young1
1Department of Rheumatology, ERAN, c/o St Albans City Hospital,
St Albans, United Kingdom; 2Department of Rheumatology,
St George’s Healthcare NHS Trust, London, United Kingdom;
3Department of Rheumatology, Sherwood Forest Hospitals NHS
Trust/University of Nottingham, Nottingham, United Kingdom;
4Department of Rheumatology, Hereford Hospitals NHS Trust,
Hereford, United Kingdom
Background: Current guidelines for management of early Rheumatoid
Arthritis (RA) include the principles of treating to a low disease activity
target, such as the 28 joint disease activity score (DAS28). Strategies
to achieve this include conventional disease modifying anti-rheumatic
drugs (DMARDs) used sequentially or in combinations and if these fail
and DAS28 remains >5.1, the use of biologic agents. This study
examines actual clinical practice in the management of early RA from
25 centres in the UK since 2002.
Methods: The Early RA Network (ERAN) is a multi-centre inception
cohort which was started in the UK in 2002 to record secondary care
management of RA and examine RA outcomes over time.
Standardised clinical and laboratory data is collected at entry and
yearly. Outcomes include measures of function (HAQ & SF36), disease
activity (DAS28), radiological erosions of hands/feet, work disability
and all interventions including drug therapies and orthopaedic surgery.
Results: 557 patients have completed three year follow up out of a
total of 1189 recruited into the study. 542 patients were on DMARD
therapy. Demographics and baseline characteristics were mean age
55.5yrs, 66% women, 61% rheumatoid factor positive, 29% had
erosions on X-rays. The time in months from first RA symptoms to first
rheumatology outpatient assessment was median 7 months, and from
the latter to start of first DMARD was 1 month. First DMARD use was
as follows: Methotrexate 45%, Sulphasalazine 37%, other mono-
therapy 7%, miscellaneous combination therapy 7%, triple therapy
4%. By 3 years, 48% were on monotherapy, 12% were on sequential
monotherapy, 29% were on ‘step up’ (‘add on’) combination therapies
and 11% had combination therapies from start. 53 (10%) of the
patients had anti-TNF agents added to their DMARD therapies. Table 1
shows the mean DAS28 over 3 years in the different DMARD groups.
The mean DAS28 was significantly lower at 6 months and 1 year in
the monotherapy group compared to each of the other groups
(p<0.0001). The results were similar at 3 years, except there was no
significant difference in DAS28 between the monotherapy and
combination therapy groups (mean 3.1 vs 3.2 respectively).
Conclusions: These results show that nearly half of these patients
remained on monotherapy over 3 years as DAS28 values were
controlled. The findings also suggest that if patients who are started on
monotherapy do not achieve a low DAS28 by 6-12 months, then more
intensive combination therapies with or without anti-TNF agents,
should be considered.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. DAS 0-3 years by drugs at FUp year - ERAN 2002–2010
Drugs 3 years
Mono Rx Seq Mono CombAddon Comb Rx
DAS 0yr mean 4.4 4.3 5.1 4.9
DAS 6mth mean 3.5 3.9 4.5 4.2
DAS 1yr mean 3.2 4.1 4.2 3.8
DAS 2yr mean 3.2 3.8 4.1 3.5
DAS 3yr mean 3.1 4.1 3.7 3.2
204. AN AUDIT OF THE USE OF RITUXIMAB AGAINST
NICE TA195
Devron Shah1, Gregory D. Knight1 and David G. Hutchinson2
1Knowledge Spa, Peninsula Medical School, Truro, United Kingdom;
2Rheumatology Department, Royal Cornwall Hospital, Truro,
United Kingdom
Background: In August 2010, NICE released TA195 for the use of
rituximab and other agents following the failure of a TNF inhibitor in the
treatment of RA. This study compared the historical use of rituximab
within our department with TA195 to determine if there is a difference
in response between those who were TA195 compliant, and those who
received rituximab according to the clinical gestalt of the consultant
rheumatologists.
Methods: A proforma captured data from all RA patients prescribed
rituximab. Patients were NICE compliant if they satisfied three criteria:
1.Patient received concomitant methotrexate (MTX) 2.Prior history of
anti-TNF use 3.Multiple treatment cycles were at least 6 months apart.
Patients were NICE non-compliant if they failed to satisfy any of these
criteria. Change in DAS28 score between baseline and three months
post-treatment was used to determine each patient’s EULAR response
to each treatment cycle. The EULAR response between the NICE
compliant and non-compliant groups was compared after the first and
second cycles of treatment (where applicable).
Results: Of 62 RA patients treated since 2006, 25 were NICE
compliant (40.3%), and 37 were non-compliant (59.7%). 20/37 were
not on MTX. A DAS28 score was lacking for 1 patient at follow-up, and
12 patients were still within the three month follow-up period.
Response to the first treatment cycle was determined for 49 of the
62 patients. Median DAS28 change was 1.985 (range -1.54 to 5.13).
To compare the NICE compliant and non-compliant groups, good
and moderate EULAR responses were considered together as
responders (Table 1). A 2 analysis tested the null hypothesis that
NICE compliance does not influence response. A 2 result of 1.400
with 1 degree of freedom was obtained (P¼0.2).
37 patients had at least 2 treatment cycles. 2 patients died prior to
follow-up, and 8 patients were still within the three month follow-up
period. EULAR response to the second treatment cycle was
determined for 27 of the 37 patients. Median DAS28 change was
2.95 (range -0.01 to 5.31). Responders and non-responders were
compared as above. A 2 result of 0.391 with 1 degree of freedom was
obtained (P¼0.5).
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Conclusions: There was no apparent difference in response between
those who were NICE compliant and non-compliant for the first and
second treatment cycles. The majority of non-compliant patients were
those who could not be prescribed concomitant MTX. According to
TA195, they should have been prescribed adalimumab or etanercept
as monotherapy. However, our clinical experience is of a good
response to rituximab irrespective of TA195 compliance. Further
published data is required to address rituximab efficacy without MTX.
Disclosure statement: D.H. has performed consultancy work for
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205. SAFETY OF RITUXIMAB IN PATIENTS WITH
RHEUMATOID ARTHRITIS AND CONCOMITANT
LUNG DISEASE
Shouvik Dass1, Fabiola Atzeni1, Edward M. Vital1,
Sarah J. Bingham1, Maya Buch1, Paul Beirne2 and Paul Emery1
1Academic Section of Musculoskeletal Disease, Leeds Teaching
Hospitals NHS Trust, Leeds, United Kingdom; 2Respiratory
Medicine, Leeds Teaching Hospitals NHS Trust, Leeds,
United Kingdom
Background: A variety of lung diseases are more common in patients
with rheumatoid arthritis (RA) - including interstitial lung disease
(ILD) and infectious conditions - and they may be considered
contraindications to or cause toxicity in patients receiving DMARDs
or anti-TNF agents. Many such patients may therefore be treated with
rituximab (RTX). The safety of RTX in lung disease in RA has not been
fully assessed and such patients are often excluded from clinical trials.
This ongoing observational study aimed to evaluate the safety of
patients with RA and lung disease that received RTX.
Methods: The records of patients who received RTX for RA at one Unit
were reviewed and patients with lung disease before RTX were
identified. Data were recorded on type of lung disease; mortality; and
serious respiratory infections (i.e. necessitating admission to hospital
or intravenous antibiotics). Patients underwent CT scanning and
pulmonary function tests at time of diagnosis of lung disease. All
patients received 2 infusions of 1,000 mg RTX with methylpredniso-
lone; this repeated on return of RA disease activity, at not less than 6
monthly intervals.
Results: 347 patients received RTX for RA between 2004 and 2010. 67
patients (19.3%) had lung disease when treated with RTX. 56 (83.6%)
of these patients were female, mean age was 60.3 þ/- 13.5 years,
mean disease duration was 15.1 þ/- 9.4 years. 34 patients (50.7%)
had received at least 2 cycles of RTX. Total follow up duration was
173.5 patient years (median 2.36, range 0.65 - 6.58 years). 48 patients
had (71.6%) had ILD; 14 patients had chronic obstructive pulmonary
disease (COPD); 5 patients had bronchiectasis; 2 patients had
previous pulmonary empyema. After RTX, 3 deaths were recorded
(2 patients with ILD, 1 patient with COPD). Causes of death were:
infective exacerbation of COPD (12 months after 3rd cycle of RTX);
pneumonia and possible acute progression of ILD - clinical and CT
changes attributable to either condition were observed(4 weeks after
1st cycle of RTX) and suicide (3 months after 1st cycle of RTX).
3 patients had single episodes of serious respiratory tract infection
(as defined above).
Conclusions: No definite new significant safety signals were observed
beyond that which might be expected in this patient population
(longstanding severe RA and concomitant lung disease). However, we
note that 1 death occurred due to respiratory deterioration closely
temporally related to RTX. Analysis of follow up respiratory function
and HRCT data is in progress, as well as ongoing safety review.
Disclosure statement: M.B., S.D. and E.V. have received honoraria
from Roche. P.E. has received consultancy fees from Roche. All other
authors have declared no conflicts of interest.
206. SUSTAINED EFFICACY IS ACHIEVED WITH MULTIPLE
COURSES OF RITUXIMAB IN PATIENTS WITH RHEUMATOID
ARTHRITIS WITH AN INADEQUATE RESPONSE TO ONE
OR MORE TNF INHIBITORS
Edward Keystone1, Roy Fleischmann2, Paul Emery3,
Maxime Dougados4, Sarah Williams5 and Mark Reynard5
1Rheumatology, University of Toronto, Toronto, ON, Canada;
2Rheumatology, University of Texas Southwestern Medical Center,
Dallas, TX, USA; 3Musculoskeletal Disease, University of Leeds,
Leeds, United Kingdom; 4Rheumatology, Hoˆpital Cochin, Paris,
France; 5PDBB, Roche Products Ltd, Welwyn Garden City,
United Kingdom
Background: To determine the effect of multiple courses of rituximab
in patients with severe, refractory RA (TNF-IR population).
Methods: Further courses of rituximab (2 x 1000 mg IV, 2 weeks apart)
were permitted in TNF-inhibitor (TNF-IR) patients who entered the
open-label extensions of the Phase II or III studies of the rituximab RA
clinical programme. Eligibility for re-treatment included a response to
the initial course (20% reduction in swollen and tender joint counts
[SJC/TJC]), with courses administered no more frequently than every
16 weeks. Re-treatment criteria were SJC and TJC 8 or DAS28 2.6
(depending on the study). Efficacy at 24 weeks post-rituximab course
was determined relative to pre-rituximab baseline. Two populations
were analysed: observed data on all patients (All patients); and
observed data on all patients with efficacy data at 24 weeks following
each of their first 5 courses of rituximab (within patient, within visit
[WW]).
Results: A total of 500 patients had been exposed to 1 course of
rituximab and had efficacy data at Week 24. The WW population
comprised 119 evaluable patients. Greater responses were observed
in all patients with rituximab re-treatment than with a single course
(Table 1). However, re-treatment criteria may cause this population to
become enriched with rituximab responders, as patients were required
to achieve a response to the first course. Responses were maintained
when analysed in the WW population (Table 1). Furthermore, 5 courses
of rituximab resulted in a doubling of the proportion of patients in
the WW population achieving DAS28 low disease activity (LDA) or
remission. No unexpected findings for rates of infection (including
serious infection) were found with rituximab re-treatment over multiple
courses.
Conclusions: Multiple courses of rituximab produce sustained
efficacy and tolerability in TNF-IR patients with active RA
Disclosure statement: M.D. has received research grants and




Response C1 C2 C3 C4 C5 C1 C2 C3 C4 C5
ACR responses (n) 500 360 289 222 153 119 119 119 119 119
ACR20 (%) 61.0 70.8 70.9 65.8 65.4 68.9 72.3 71.4 67.2 70.6
ACR50 (%) 30.2 41.4 46.4 43.2 42.5 35.3 41.2 45.4 42.9 44.5
ACR70 (%) 12.0 18.9 25.3 22.5 20.3 16.0 18.5 23.5 21.0 22.7
EULAR responses (n) 489 355 288 215 149 112 112 112 112 112
Good response (%) 15.7 25.4 33.3 28.8 28.2 10.7 20.5 25.9 23.2 30.4
DAS28 LDA (%) 16.2 25.6 33.7 28.8 28.2 11.6 20.5 25.9 23.2 30.4
DAS28 remission (%) 8.4 14.4 17.7 17.2 16.1 6.3 8.9 9.8 15.2 15.2
Change in DAS28 489 355 288 215 149 112 112 112 112 112
Mean change 2.15 2.64 2.93 2.88 2.93 2.29 2.63 2.83 2.85 3.08
SD 1.43 1.43 1.46 1.59 1.73 1.32 1.46 1.46 1.67 1.66
C: course; LDA: DAS28 3.2; remission: DAS28 <2.6.
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207. NURSE-SPECIALIST-LED CLINICS SIGNIFICANTLY
IMPROVE PATIENT CONCORDANCE WITH DMARD THERAPY
IN RA: A CRITICAL STEP IN ACHIEVING REMISSION
Laura Blackler1, Nicola J. Gullick1,2, Amir Zain1, Stephen Oakley1,3,
Jonathon Rees1,4, Tim Jones1,4, Alan Mistlin1,4, Gabriel Panayi1,2 and
Bruce W. Kirkham1
1Rheumatology, Guy’s & St Thomas’ NHS Foundation Trust, London,
United Kingdom; 2Rheumatology, King’s College London, London,
United Kingdom; 3Rheumatology, Royal Newcastle Centre,
Newcastle, NSW, Australia; 4Rheumatology, DMRC Headley Court,
Epsom, United Kingdom
Background: In the absence of a cure, the ultimate goal of treatment
for Rheumatoid Arthritis (RA) is remission, which is associated with
improved long-term outcomes. Goal directed therapy is necessary to
achieve the target of remission. Tight control with rapid optimization of
DMARD therapy and patients understanding the goal of therapy are
essential if this is to be achieved. The RA Centre aims to achieve
remission defined by a DAS28 score <2.6 in all patients if possible,
using all available medication within national guidelines. We have
investigated the outcomes of consultations over several years to
understand the detail of this strategy and the obstacles to achieving it.
One such obstacle was patients declining treatment and two audits in
2004 and 2006 showed that 35% of patients were declining an
increase in treatment.
Methods: A retrospective notes review using the same pro-forma as
previous audits was carried out for sequential RA consultations. The
primary question investigated reasons for no change in therapy if
DAS28 was >2.6. There were six categories identified for no change in
therapy and we also analysed patient related factors influencing
treatment decisions. We compared the results of this audit with two
previous audits of outcome of consultations conducted using the same
pro-forma in 2004 and 2006.
Results: 200 patient visits were reviewed and there were 160 women
and 40 men, 130 had a change in treatment and 70 had no change.
The majority of the patients (151) were white/white British, age range
22-89 years, disease duration less than 1 year to 43 years and DAS28
scores ranging from 2.7 to 7.5. A number of factors were identified as
to why there was no change in treatment (see Table 1).
Conclusions: This study shows that the number of patients declining
treatment has decreased significantly form 35% in the first two audits
to only 8%. The reasons for this change are probably multifactorial.
The RA Centre clinic has evolved and the ethos of goal directed
therapy is now firmly embedded at the centre of patient care and has
become part of routine practice, it is expected that remission can be
achieved. We believe that the most important change over the last four
years has been the introduction of the clinical nurse specialist role to
provide support to newly diagnosed patients guiding them through the
first few months of diagnosis and treatment, providing education and
encouragement. Patients are seen on a monthly basis for a review of
their medication and dose escalation of DMARDs.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
Reasons 2010 2006 2004
Number of patients 70 29 81
Declined 8% 35% 34%
Pain score>inflammation 30% 20% 5%
Contraindications 8% 17% 22%
Flare-up only 4% 10% 15%
Waiting for previous treatment to take effect 28% 6% 12%
Other reasons 22% 12% 12%
208. DISEASE REMISSION, NORMALIZED PHYSICAL
FUNCTION AND RADIOGRAPHIC NON-PROGRESSION
ARE ACHIEVED BY THE MAJORITY OF PATIENTS WITH
EARLY RHEUMATOID ARTHRITIS TREATED WITH
ABATACEPT þ METHOTREXATE: RESULTS FROM THE
2-YEAR AGREE TRIAL
Rene Westhovens1, Patrick Durez2, Harry Genant3, Manuel Robles4,
Jean-Claude Becker5, Allison Covucci5 and Joan Bathon6
1Department of Rheumatology, UZ Gasthuisberg, Leuven, Belgium;
2Department of Rheumatology, Cliniques Universitaires Saint-Luc,
Brussels, Belgium; 3Department of Rheumatology, University of
California, San Francisco, CA, USA; 4Rheumatology Department,
Centro Me´dico Toluca, Metepec, Mexico; 5Bristol-Myers Squibb,
Bristol-Myers Squibb, Princeton, NJ, USA; 6Division of
Rheumatology, John Hopkins University School of Medicine,
Baltimore, MD, USA
Background: Earlier, more intensive treatments in early RA pts have
made disease remission and normalized physical function attainable
goals. Prevention of radiographic progression early in disease is
pivotal to minimizing detrimental long-term outcomes. We evaluated
clinical and radiographic outcomes with abatacept (ABA)þmetho-
trexate (MTX) over 2 yrs in MTX-naı¨ve early RA pts.
Methods: In AGREE, early RA pts with poor prognostic factors were
randomized to ABA (10 mg/kg)þMTX or placebo (PBO)þMTX in a
1-yr double-blind period; all pts received ABAþMTX in a 1-yr open-
label (OL) period. Efficacy and safety were assessed for pts who
received 1 dose of OL ABA. Disease Activity Score 28 (DAS28
[CRP])-defined remission (DAS28 <2.6) and tender/swollen (active)
joints (28-joint count) were assessed for the modified intent-to-treat
population (dropouts¼ non-responders). Normalized physical function
(Health Assessment Questionnaire-Disability Index [HAQ-DI] score
0.5) and radiographic progression (mean change in Genant-modified
Sharp total scores [TS] and non-progression¼ change from baseline
in TS 0) were assessed as-observed.
Results: 459 pts (both arms) completed Yr 1 and continued in Yr 2;
94.3% completed Yr 2. Mean baseline DAS28 (CRP)¼6.3; HAQ-DI
score¼1.7; TS¼ 7.5. Proportion of pts randomized to ABAþMTX
achieving remission was maintained (46.1 vs 55.2% at Yrs 1 and 2). Of
pts in remission at Yr 2, 63.5% had 0 active joints; 11.9, 7.1 and 17.5%
had 1, 2 and3 active joints, respectively. For the PBOþMTX arm,
26.9% achieved remission at Yr 1; after switching to ABAþMTX,
44.5% achieved remission at Yr 2. HAQ-DI normalization was
maintained over 2 yrs for the ABAþMTX arm, with rates of 49.1
and 54.7% at Yrs 1 and 2; rates for the PBOþMTX arm were 35.6% at
Yr 1 and 47.6% at Yr 2 after addition of ABA. Pts randomized to
ABAþMTX had significantly less structural damage progression in Yr
2 vs Yr 1 (change in TS: 0.65 from baseline to Yr 1 vs 0.18 from Yr 1-2;
p<0.001). For pts randomized to PBOþMTX, change in TS was 1.48
from baseline to Yr 1 vs 0.25 from Yr 1-2; p<0.001. Changes from
baseline to Yr 2 were significantly lower for the original ABAþMTX arm
vs those who switched at Yr 1; 0.84 vs 1.75, p¼0.001. The rate of non-
progression over 2 yrs was 56.8% in the ABAþMTX arm vs 43.8% in
the PBOþMTX arm; 91.1% of pts randomized to ABAþMTX who
were non-progressors at Yr 1 remained non-progressors at Yr 2. AEs,
including serious infections, malignancies and autoimmune events, in
Yr 2 were consistent with those in Yr 1.
Conclusions: Early introduction of ABAþMTX combination therapy
results in greater sustainable clinical and radiographic benefits and
normalization of function in the majority of MTX-naı¨ve early RA pts vs
MTX alone, supporting use of ABAþMTX earlier in disease.
Disclosure statement: J.B. has received Grant or research support
from Biogen Idec and Pfizer and is a consultant for Crescendo
Biosciences. J.B. is an employee and shareholder of Bristol-Myers
Squibb and has a self-directed pension plan with Bristol-Myers
Squibb. A.C. is an employee of Bristol-Myers Squibb. P.D. is/has
been a member of speakers’ bureaus for Wyeth, Bristol-Myers Squibb
and Schering-Plough. H.G. has received grants or research support
from and is a consultant for Bristol-Myers Squibb, Roche, Genentech,
Amgen and Merck, has received research support from Pfizer, Servier
and Biogen Idec, and is a consultant and shareholder of Synarc. R.W.
has received research support from UCB, is/has been a consultant
and member of speakers’ bureaus for Bristol-Myers Squibb and
Schering-Plough, and is a consultant for Roche Belgium. All other
authors have declared no conflicts of interest.
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209. SAFETY, EFFICACY AND HEALTH-RELATED QUALITY
OF LIFE THROUGH 5 YEARS OF ABATACEPT TREATMENT
IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN
INADEQUATE RESPONSE TO ANTI-TUMOUR NECROSIS
FACTOR THERAPY
Mark C. Genovese1, Michael Schiff2, Michael Luggen3,
Manuela Le Bars4, Jean-Claude Becker5, Richard Aranda5, Tracy Li5,
Ayanbola Elegbe5 and Maxime Dougados6
1Division of Immunology and Rheumatology, Stanford University,
Palo Alto, CA,USA; 2Rheumatology Division, University of Colorado,
Denver, CO, USA; 3Rheumatology Department, University of
Cincinnati Medical Center, Cincinnati, OH, USA; 4Bristol-Myers
Squibb, Bristol-Myers Squibb, Rueil-Malmaison, France;
5Bristol-Myers Squibb, Bristol-Myers Squibb, Princeton, NJ, USA;
6Rheumatology Department, Hospital Cochin, Paris, France
Background: Abatacept (ABA) has shown sustained efficacy and
consistent safety over the long term in patients (pts) with RA and
an inadequate response (IR) to anti-TNF therapy in the ATTAIN trial.
Here we evaluate the safety, efficacy and health-related quality of life
(HRQoL) of ABA through 5 years (yrs) in anti-TNF inadequate
responders.
Methods: Pts in this placebo-controlled Phase III trial had active RA
and an IR to 3 months anti-TNF therapy. Pts completing a 6-month
double-blind (DB) period entered a long-term extension (LTE) to
receive 10 mg/kg ABAþbackground DMARDs. Pts left the study
after 5 yrs of treatment or when ABA became commercially available in
their country. Safety was assessed for pts who received 1 ABA dose
during the LTE up to November 2008 (5 yrs). Disease Activity Score
28 (DAS28, based on C-reactive protein [CRP]), Health Assessment
Questionnaire-Disability Index (HAQ-DI) and Short Form (SF)-36
scores (physical component summary [PCS] and mental component
summary [MCS]) were assessed for pts randomized to ABA who
entered the LTE, using as-observed data. DAS28 (CRP) data are
presented to Yr 4.5 (6-month DBþ 4-yr LTE) and HAQ-DI and SF-36
data to Yr 4 (6-month DBþ 3.5-yr LTE).
Results: 317/322 completers of the DB period entered the LTE (218/
317 had been randomized to DB ABA). ABA-treated pts who entered
the LTE had mean DAS28 (CRP) of 6.5 and mean HAQ-DI score of 1.8
at baseline. Mean exposure (range) to ABA was 42.2 (3.7-65.5)
months. During the LTE, 69/317 (21.8%) and 36/317 (11.4%) pts
discontinued due to lack of efficacy and adverse events (AEs),
respectively. Incidence rates (per 100 pt-yrs) of serious AEs and
serious infections were 26.0 and 5.3 versus 19.6 and 3.4 in the DB
period vs the LTE, respectively. No cases of tuberculosis or
opportunistic infections occurred in the LTE. Rates of malignancies
and autoimmune events per 100 pt-yrs, respectively, were 3.5 and 1.8
in the DB period vs 2.2 and 1.5 in the LTE. Five deaths (respiratory
distress, asphyxia, staphylococcal wound infection, metastatic neo-
plasm, natural cause) occurred in the LTE. Reductions in DAS28 were
observed through the LTE: mean changes (95% CI) from baseline were
-2.0 (-2.2, -1.8) at Month 6 vs -2.9 (-3.1, -2.6) at Yr 4.5. Reductions
in HAQ-DI score were maintained from Month 6 through the LTE: -0.5
(-0.6, -0.4) at Month 6 and -0.6 (-0.7, -0.5) at Yr 4. Improvements from
baseline in PCS and MCS were maintained during the LTE, with 7.5
(6.1, 8.8) and 5.8 (4.2, 7.5) at Month 6 vs 8.7 (6.9, 10.5) and 5.4 (3.2,
7.6) at Yr 4, respectively.
Conclusions: During the ATTAIN LTE, ABA was well tolerated with
consistent safety relative to the DB period. Improvements in disease
activity, physical function and HRQoL observed in the DB period were
sustained in the LTE, supporting long-term use of ABA in anti-TNF
inadequate responders.
Disclosure statement: R.A. is and employee and shareholder of
Bristol-Myers Squibb. J.B. is an employee and shareholder of Bristol-
Myers Squibb and has a self-directed pension plan. M.D. has received
research support from and is a consultant for Bristol-Myers Squibb,
Abbott, Wyeth, Centocor and Schering-Plough, and is a member of
speakers’ bureaus for Bristol-Myers Squibb, Abbott and Wyeth. A.E.
and M.L. are employees and shareholder of Bristol-Myers Squibb.
M.G. has received research grants and consultancy fees from, and is a
member of a speakers’ bureau for Bristol-Myers Squibb. T.L. was an
employee and shareholder of Bristol-Myers Squibb at the time of the
study. M.L. has received research support from Bristol-Myers Squibb.
M.S. has received research support from and is a consultant for
Bristol-Myers Squibb.
210. EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL
PLUS METHOTREXATE IN PATIENTS WITH RHEUMATOID
ARTHRITIS: 3-YEAR DATA FROM THE RAPID 2 STUDY
Josef Smolen1, Ronald van Vollenhoven2, Arthur Kavanaugh3,
Andreas Fichtner4, Vibeke Strand5, Jiri Vencovsky6 and
De´sire´e van der Heijde7
1Department of Rheumatology, Medical University of Vienna and
Hietzing Hospital, Vienna, Austria; 2Rheumatology Unit, Department
of Medicine, Karolinska Institute, Stockholm, Sweden;
3Rheumatology Division, UCSD, San Diego, CA, USA; 4Global
Biostatistics, UCB, Monheim, Germany; 5Department of Medicine,
Stanford University, Palo Alto, CA, USA; 6Medicine, Institute of
Rheumatology, Prague, Czech Republic; 7Rheumatology,
Leiden University Medical Center, Leiden, Netherlands
Background: Certolizumab pegol (CZP) every other week (EOW)þ
methotrexate (MTX) demonstrated rapid and sustained efficacy with
an acceptable tolerability profile over 2 years (yrs) in patients (pts) with
active rheumatoid arthritis (RA) despite MTX. The purpose of this
analysis is to evaluate sustainability of improvements in RA signs and
symptoms, inhibition of joint damage progression and tolerability of
CZPþMTX over 3 yrs in pts who completed 24 weeks (wks) of double-
blind treatment with CZP 200 or 400 mg EOWþMTX (completers) in
RAPID 2, and entered an open-label extension (OLE) of CZP 400 mg
EOWþMTX (CZP 400 mg EOW is not licensed in the UK).
Methods: ACR responses, DAS28(ESR), HAQ-DI, pain VAS (0-100 mm
scale) were measured over 3 yrs (148 wks) from RAPID 2 baseline (BL)
for CZP completers who entered OLE; modified Total Sharp Scores
(mTSS) were measured over 2.5 yrs (128 wks). Pts who withdrew from
the OLE for any reason or took rescue medication in the OLE had data
imputed from that timepoint onward. For mTSS, linear extrapolation
was used. For DAS28, HAQ-DI, and pain VAS, last observation carried
forward was used for any missing data. For ACR responses, both non-
responder imputation (NRI) and observed data are reported. AEs were
assessed in all pts at each visit (after first study drug administration)
from RAPID 2 BL. Safety analyses were based on the ITT population.
AEs and serious AEs (SAEs)/100 pt-yrs are presented for all pts who
received 1 CZP dose. RAPID 2: NCT00160602; RAPID 2 OLE:
NCT00160641.
Results: Of 494 pts treated with CZPþMTX, 355 completed RAPID 2;
of these, 342 (96%) entered the OLE. Completers entering OLE had
high disease activity at RAPID 2 BL (mean: DAS28: 6.8; HAQ-DI: 1.6;
pain VAS: 60.7); mean mTSS at RAPID 2 BL was 33.6. After 3 yrs, 79%
of CZP completers continued to receive OL CZP; only 2 pts withdrew
due to lack of efficacy. ACR responses and improvements in DAS28,
HAQ-DI and pain from BL were sustained in the OLE to 3 yrs in CZP
completers. After 3 yrs, 60% and 32% of patients were ACR50 and
ACR70 responders, respectively (observed case analysis). Similar
response patterns were obtained using NRI. Mean change from BL at
3 yrs in DAS28, HAQ-DI and pain VAS was 3.0, 0.65 and 29.2,
respectively. Inhibition of progression of structural damage observed
during the placebo-controlled phase was sustained up to the last x-ray
evaluation at 2.5 yrs (mTSS mean change from BL: 0.75). The
incidence of AEs by Wk 148 was 108/100 pt-yrs, and SAEs
13/100 pt-yrs. Most AEs were mild to moderate; no new safety signals
were identified.
Conclusions: In pts with active RA despite MTX, the addition of CZP
provides clinical improvements that are sustained over 3 yrs, inhibits
joint damage progression, and is well tolerated.
Disclosure statement: A.F. is an employee of UCB. A.K., J.S. and
R.V. have received research support from and are consultants for
UCB. V.S. and D.V. are consultants for UCB. J.V. is/has been a
member of a speakers’ bureau for UCB.
211. ARE VENOUS THROMBOTIC EVENTS INCREASED IN
PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH
ANTI-TNF THERAPY? RESULTS FROM THE BRITISH SOCIETY
FOR RHEUMATOLOGY BIOLOGICS REGISTER (BSRBR)
Rebecca Davies1, James Galloway1, Kath D. Watson1, Mark Lunt1,
BSRBR Control Centre Consortium1, Deborah Symmons1 and
Kimme L. Hyrich1 on behalf of the British Society for Rheumatology
Biologics Register
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, United Kingdom
Background: Case reports have shown that TNF decreases platelet
activation and inhibits thrombus formation, and so blocking TNF may
contribute to thrombus formation. Research looking at the role of such
therapies on venous thrombotic events (VTE) in RA patients been
conflicting. The aims of this analysis were (1) to compare rates of VTE
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in RA patients treated with anti-TNF vs. non-biologic disease
modifying anti-rheumatic drugs (nbDMARDs) alone and (2) to compare
the rates between each individual anti-TNF and nbDMARDs.
Methods: To 31/10/2009, 11,173 anti-TNF and 3,214 biologic-naive
nbDMARD control patients had been recruited to the BSRBR, a UK
national register of active RA patients on biologic therapy. All patients
were followed by regular hospital and patient questionnaires. This on-
drug analysis, limited to first biologic only, followed all patients until
first VTE (deep venous thrombosis or pulmonary embolism), death,
treatment discontinuation or last follow-up date, whichever came first.
Cox proportional hazards models were used to compare rates of VTE
between cohorts. Inverse probability of treatment weighting (IPTW)
was used to adjust for the confounding effect of baseline differences
between groups, including age, gender, steroid use, smoking, disease
duration, and severity amongst others. Surgery was included as a
time-varying covariate, with patients viewed as being at increased risk
for 90 days post-procedure. Missing baseline data were accounted for
using multiple imputation.
Results: The anti-TNF cohort was younger (mean 56 v 60 years), had a
higher proportion of females (76 v 72%) and more severe disease
(mean DAS28/HAQ: anti-TNF 6.6/2.0, nbDMARD 5.1/1.5). The median
duration of follow up was 4.3 years (IQR 2.9, 5.4) in the anti-TNF
cohort, and 3.0 years (IQR 1.7, 4.2) in the nbDMARD cohort. A total of
161 first VTE’s were reported (129 anti-TNF, 32 nbDMARD). 14% of
anti-TNF and 6% of nbDMARD VTE events were reported within 90
days of hip or knee replacement. Overall there was no difference in the
rate of VTE between anti-TNF and nbDMARD treated patients
(adjusted HR 1.2 (95% CI 0.6, 2.1) (Table 1). The risk was similar
across all anti-TNF agents.
Conclusions: Anti-TNF therapy is not associated with an increased
risk of VTE in RA patients. There is also no difference in VTE risk
between the anti-TNF drugs.
Disclosure statement: The authors have declared no conflicts of
interest.
212. LONG-TERM SAFETY OF ABATACEPT: INTEGRATED
ANALYSIS OF CLINICAL PROGRAMME DATA OF UP TO
SEVEN YEARS OF TREATMENT
Marc Hochberg1, Rene Westhovens2, Richard Aranda3,
Sheila Kelly3, Nadar Khan3, Keqin Qi3, Ramesh Pappu3,
Ingrid Delaet3, Allison Luo3, Anne Torbeyns4, Larry Moreland5,
Roger Cohen6, Sheila Gujrathi3 and Michael Weinblatt7
1Department of Medicine, Division of Rheumatology, Baltimore, MD,
USA; 2Department of Rheumatology, Catholic University of Leuven,
Leuven, Belgium; 3Bristol-Myers Squibb, Princeton, NJ, USA;
4Bristol-Myers Squibb, Braine-l’Alleud, Belgium; 5Department of
Rheumatology, University of Pittsburgh, Pittsburgh, PA,USA; 6Fox
Chase Cancer Center, Philadelphia, PA, USA; 7Department of
Rheumatology and Immunology, Brigham & Women’s Hospital,
Boston, MA, USA
Background: Integrated analyses of clinical trial data are important to
assess long-term (LT) safety and detect rare events. Here we present
an integrated analysis of safety data from the abatacept RA clinical trial
program up to December 2009, including 12,132 patient-years (p-y) of
exposure.
Methods: Data from eight abatacept RA clinical trials were classified
into short-term (ST) and LT periods and analyzed. ST data included
six double-blind (6- or 12-month), placebo-controlled periods, one
non-randomized Phase II study and one non-randomized Phase III
study. The LT data included the open-label (OL) periods of these eight
studies. Safety assessments, presented for all patients receiving 1
dose of abatacept, included adverse events (AEs), serious AEs (SAEs),
mortality and events of clinical interest. All events are presented as
incidence rates (IRs) per 100 p-y with 95% CIs.
Results: The cumulative period (ST and LT) included 4149 patients
with 12,132 p-y of exposure; 1165 had 5 years’ exposure. Mean
(range) exposure was 35.6 (1.9-104.2) months. The ST period included
3173 patients (2331 p-y) and the LT period included 3256 patients
(9752 p-y). In the cumulative period, IRs (95% CIs) for SAEs, deaths,
serious infections and autoimmune events were 14.61 (13.85-15.41),
0.60 (0.47-0.76), 2.87 (2.57-3.19) and 1.99 (1.74-2.26), respectively
and were generally consistent with IRs in the ST period. Annual IRs
(95% CIs) for SAEs did not increase with increasing abatacept
exposure: Year 1, 19.13 (17.67-20.67); Year 2, 14.39 (12.80-16.11);
Year 3, 12.82 (11.09-14.74); Year 4, 10.53 (8.76-12.57); Year 5, 10.18
(8.11-12.62); Year 6, 7.09 (4.54-10.55); Year 7, 8.90 (4.74-15.22).
During the cumulative period, the IR (95% CI) of hospitalized infection
was 2.64 (2.35-2.95). There were few opportunistic infections (0.36
[0.27-0.49]), with only eight cases of tuberculosis (0.07 [0.03-0.13])
observed overall. IRs (95% CIs) for malignancies (not including non-
melanoma skin cancer [NMSC]), NMSC and solid tumors in the
cumulative period were 0.73 (0.58-0.89), 0.73 (0.58-0.90) and 0.59
(0.46-0.75), respectively and were consistent with the ST. IRs (95%
CIs) for lung cancer and lymphoma were 0.15 (0.09-0.23) and 0.07
(0.03-0.14), respectively. Acute infusional events, occurring within one
hour of the start of the infusion, were reported at an IR (95% CI) of 3.90
(3.52-4.32; based on 6 studies).
Conclusions: Integrated safety data from 4149 patients with 12,132
p-y of exposure up to 7 years demonstrate that abatacept is generally
well tolerated. No new safety events were identified over time, and the
types and IRs of safety events (including events of clinical interest) in
the LT and cumulative periods were generally consistent with those in
the ST period, indicating that the abatacept safety profile remains
stable with increasing duration of exposure.
Disclosure statement: R.A., I.D., S.K. and A.L. are employees and
stock holders of Bristol-Myers Squibb. R.C. has received consultancy
fees from Bristol-Myers Squibb and Human Genome Sciences. S.G.,
N.K., R.P., K.Q. and A.T. are employees of Bristol-Myers Squibb. M.H.
has received consultancy fees from Abbott, Amgen, Bristol-Myers
Squibb, Genentech, Biogen Idec, Roche and UCB. L.M. has received
consultancy fees from and is a member of speakers’ bureaus for
Bristol-Myers Squibb, Genentech and Biogen Idec. R.W. has received
consultancy fees from Bristol-Myers Squibb, Centocor, Roche,
Schering-Plough and UCB, and is a member of a speakers’ bureau
for Bristol-Myers Squibb. All other authors have declared no conflicts
of interest.
213. ACT-SURE PRELIMINARY RESULTS: TOCILIZUMAB
TREATMENT OF PATIENTS WITH RA AND AN INADEQUATE
RESPONSE TO DMARDS AND/OR TNF INHIBITORS IN A
SETTING CLOSE TO CLINICAL PRACTICE
Vivian P. Bykerk1, Jose A´lvaro-Gracia2, Jose Andres Roman Ivorra3,
Michael T. Nurmohamed4, Karel Pavelka5, Corrado Bernasconi6,
Andrea Stancati6, Jean Sibilia7, Andrew O¨sto¨r and the ACT-SURE
Study Group8
1Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada;
2Rheumatology, Hospital Universitario de La Princesa, Madrid,
Spain; 3Rheumatology, Hospital Universitario Dr. Peset, Valencia,
Spain; 4Rheumatology, Jan van Breemen Institute, Amsterdam,
Netherlands; 5Rheumatology, Institute of Rheumatology, Prague,
Czech Republic; 6Rheumatology, Roche, Basel, Switzerland;
7Rheumatology, Hautepierre Service de Rhumatologie, Strasbourg,
France; 8Rheumatology, Addenbrookes Hospital, Cambridge,
United Kingdom
Background: The safety and efficacy of tocilizumab (TCZ) have been
demonstrated in patients (pts) with RA and previous inadequate
response to DMARDs (DMARD-IR) or TNF inhibitor (TNF-IR) therapy in
TABLE 1. Patient characteristics and incidence of VTEs
nbDMARD All anti-TNF ETN INF ADA
Subjects (n) 3214 11173 3968 3347 3858
Exposure (pyrs) 8702 33638 14797 8909 9932
Surgeries (n) 1145 5310 2405 1341 1564
Hip/knee replacement (n) 521 3135 1426 815 894
VTEs (n) 32 129 47 47 35
VTE within 90 days of
surgery, n (%)
4 (13) 23 (18) 9 (19) 9 (19) 5 (14)
VTE within 90 days of
hip/knee replacement, n (%)
2 (6) 18 (14) 7 (15) 8 (17) 3 (9)
VTE incident rate/1000 pyrs 3.8 (2.5,5.2) 3.8 (3.2,4.6) 3.2 (2.3,4.2) 5.3 (3.9,7.0) 3.5 (2.5,4.9)
VTE adjusted HR Ref 1.2 (0.6,2.1) 1.0 (0.5,1.9) 1.5 (0.8,2.8) 1.1 (0.5,2.3)
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7 Phase III controlled studies. However, data regarding pts switching
to TCZ without TNF inhibitor washout are limited.
Methods: ACT-SURE was a 6-month, Phase IIIb, open-label, single-
arm study of DMARD-IR and TNF-IR pts treated with TCZ 8 mg/kg
q4wk as monotherapy or in combination with DMARDs in a clinical
setting (tertiary academic centres, non-academic centres and private
practice). For analysis pts were stratified by pre-study TNF inhibitor
use (TNFi-naive [DMARD-IR] pts; previous TNFi users [>2 months
since use] or recent TNFi users [2 months since use]). A separate
sub-analysis was performed on patients receiving TCZ as
monotherapy.
Results: 1,681 pts were evaluated; mean age was 54 yrs and 81%
were female. Overall, 58% of pts were DMARD-IR, 18% were previous
TNFi users and 24% recent TNFi users. Baseline DAS28 was similar
between groups (5.9-6.2) and mean RA duration was 8.2 years for
DMARD-IR pts vs 11.2/11.7 years in previous/recent TNFi users.
Overall, 12.8% of pts withdrew, 4.8% for safety reasons, with
infections the most common safety-related cause of withdrawal
(1.1%, 1.8/100 patient-years [PY]). AE, SAE and infection rates were
lower in DMARD-IR pts. Few pts experienced clinically significant ALT
shifts. Onset of efficacy was rapid and increased over time: 24%-38%
of pts achieved DAS28 remission at Wk 8 and 49%-62% of pts at Wk
24. Responses were similar for recent and previous TNFi pts and
better among DMARD-IR pts. Mean DAS28 values at Wk 24 were 2.83/
2.76 for previous/recent TNFi users, and 2.34 for DMARD-IR pts.
Improved physical function was seen in 74.1%, 71.1% and 70.2% of
DMARD-IR pts, previous TNFi users and recent TNFi users. With TCZ
monotherapy, ACR20/50/70 response rates were 66.9%/43.5%/
23.8% at Week 24, with a DAS28 remission rate of 49.8%.
Conclusions: In a setting close to clinical practice, the TCZ safety
profile demonstrated in previous Phase III trials was confirmed. TCZ
showed rapid and increasing efficacy over time as monotherapy or in
combination with DMARDs, as first-line biologic in DMARD-IR pts and
in TNFi-IR pts. Safety results did not differ between previous and
recent TNFi users, supporting switching to TCZ without a washout.
Disclosure statement: C.B. and V.B. have received consultancy
fees from Roche. J.I. has received research grants from Actelion
Pharmaceuticals US, Merck Sharp & Dohme, Pfizer and Roche, and
consultancy fees from Actelion Pharmaceutical US. M.N. has received
research grants from Abbott Immunology Pharmaceuticals, Bristol-
Myers Squibb, Roche, Sanofi-Aventis, Schering-Plough and Wyeth, is/
has been a member of speakers’ bureaus for Abbott Immunology
Pharmaceuticals and Bristol-Myers Squibb, and has eceived con-
sultancy fees from Roche. K.P. has received consultancy fees from
Roche. A.S. is an employee of Roche. J.A. has received consultancy
fees from Roche and UCB, Inc. A.O. has received consultancy fees
from Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline,
AsahiKASEI, Merck Serono, Roche, Schering-Plough, UCB and
Wyeth, and is a member of speakers’ bureaus for Abbott
Laboratories, Bristol-Myers Squibb, Chugai, Merck Serono, Roche,
Schering-Plough and UCB. All other authors have declared no
conflicts of interest.
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> 3 x ULN
% (n)
DMARD-IR 551.1 18.6 4.2 6.8 (66) 2.4 (23)
TNFi-IR,
previous
654.4 28.7 7.6 7.4 (22) 3.0 (9)
TNFi-IR,
recent











DMARD-IR 70.5 (688) 51.9 (507) 31.8 (310) 10.3 (101) 61.6 (534/867)
TNFi-IR,
previous
60.7 (181) 35.2 (105) 17.8 (53) 6.4 (19) 48.5 (117/241)
TNFi-IR,
recent
62.7 (255) 42.3 (172) 19.7 (80) 6.6 (27) 50.4 (175/347)
n/n: no. of patients who responded/no. of evaluable patients. *Infusion reaction:
AE occurring during infusion of TCZ.
214. THE IMPACT OF ESR ON TREATMENT RESPONSE
RATES IN PATIENTS TREATED WITH TOCILIZUMAB IN DAILY
CLINICAL PRACTICE: FINDINGS FROM THE GERMAN
BIOLOGICS REGISTER (RABBIT)
Anja Strangfeld1, Maria Eveslage1, Joachim Listing1, Peter Herzer2,
Anke Liebhaber3, Brigitte Krummel-Lorenz4 and Angela Zink1,5
1Epidemiology Unit, Deutsches Rheuma-Forschungszentrum Berlin,
Berlin, Germany; 2Scientific Advisory Board, Mu¨nchen, Germany;
3Private practice, Halle/S, Germany; 4Private practice, Frankfurt/M,
Germany; 5Rheumatology and clinical Immunology, Charite´
University Hospital, Berlin, Germany
Background: Tocilizumab, a human anti-interleukin (IL)-6 receptor
antibody, has demonstrated high clinical response and remission rates
in clinical studies of patients with RA and has recently been approved
for the treatment of this condition. IL-6 receptor blockade leads to a
direct inhibition of acute-phase protein production by hepatocytes. C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR), which
are measures of the acute-phase response, are important components
of the disease activity score (DAS28) used to determine treatment
effectiveness in RA. The present study investigated the contribution of
single components of the DAS28 to treatment response in tocilizumab-
treated patients in daily rheumatological care.
Methods: The RABBIT register is a prospective cohort study
containing data on all licensed biologic agents prescribed to RA
patients in Germany since 2001. Following the approval of tocilizumab
in Germany in January 2009, patients starting treatment with
tocilizumab were enrolled in the study. All patients included in the
register will undergo 5 years’ follow-up, including regular assessments
of clinical status and therapy, with disease activity measured using
DAS28 (ESR).
Results: Of 6,861 enrolled patients in the register, 243 patients
received treatment with tocilizumab. Mean age and median disease
duration at start of treatment were 57 years and 10 years. Of patients
with 3 months’ follow-up (n¼ 119), 36% achieved a good EULAR
response with a further 29% achieving a moderate response. DAS28
remission (DAS28< 2.6) was achieved by 27% of patients. Of 55
patients with 6 months’ follow-up, 49% had a good EULAR response,
with an additional 29% having a moderate response; 40% of patients
were in DAS28 remission. With regard to single DAS28 components,
similar changes in joint counts and patient global assessment were
observed in patients treated with tocilizumab compared to patients
receiving other biologics whereas the decrease in ESR levels was
significantly greater. The percental change of the ESR after 6 months
was 80% under treatment with tocilizumab compared to 33% under
anti-TNF treatment. In a high number of patients treated with
tocilizumab the decrease in ESR was already sufficient to reach
EULAR response.
Conclusions: A substantial proportion of RA patients treated with
tocilizumab in clinical practice benefit from high response and
remission rates. However, when considering treatment efficacy
based on DAS28 and EULAR responses, the significant impact of
ESR changes on these outcome measures must be taken into
account.
Funding: The RABBIT register is supported by a joint, undconditional
grant from Abbott, Amgen/Biovitrum, Essex, Bristol-Myers Squibb,
Pfizer, Roche and UCB Germany.
Disclosure statement: A.S. has received honoraria from Pfizer, Roche
and Bristol-Myers Squibb. All other authors have declared no conflicts
of interest.
215. CHANGE IN CRP AT 12 WEEKS PREDICTS THE RISK OF
RAPID RADIOGRAPHIC PROGRESSION AT TWO YEARS IN
METHOTREXATE-TREATED PATIENTS WITH EARLY
RHEUMATOID ARTHRITIS
Boulos Haraoui1, Paul Emery2, Neelufar Mozaffarian3,
Benoit Gue´rette4, Hartmut Kupper5, Kaushik Patra3 and
Edward Keystone6
1Medicine: Rheumatology, Centre Hospitalier de I’Universite´ de
Montre´al (CHUM, Hoˆpital Notre-Dame), Montre´al, QC, Canada;
2Academic Section of Musculoskeletal Medicine in the Institute of
Molecular Medicine, Leeds Teaching Hospital, Leeds,
United Kingdom; 3Global Pharmaceutical Research and
Development, Abbott, Abbott Park, IL,USA; 4Global Pharmaceutical
Research and Development, Abbott, Rungis, France; 5Global
Pharmaceutical Research and Development, Abbott GmbH & Co,
Ludwigshafen, Germany; 6The Rebecca MacDonald Centre for
Arthritis and Autoimmune Disease, Mount Sinai Hospital, University
of Toronto, Toronto, ON, Canada
Background: In patients with rheumatoid arthritis (RA), radiographic
progression is an important contributor to long-term disability. Hence,
identifying patients at risk of rapid radiographic progression (RRP)
early in the course of disease is an important goal of medical
management, as it affects therapeutic decision-making. The objective
of this study was to determine whether change in CRP after 12 weeks
of treatment can indicate risk of RRP in patients with early RA.
Methods: We examined data from methotrexate (MTX)-naı¨ve patients
with early RA in the PREMIER study, a 104-week, phase 3, placebo-
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controlled trial in which patients were randomized 1:1:1 to the
following: weekly MTX, adalimumab (ADA) 40 mg every other week,
or ADAþMTX. This post hoc analysis evaluated patients from the
intent to treat population who had CRP measures available at baseline
and at week 12, as well as radiographs available at baseline and week
104. RRP was defined as an increase of >3 units/year in the modified
Total Sharp Score (mTSS). Using week 12 data, quartiles (Qs) of CRP
absolute values and percent change from baseline (%CRP) were
used to assess relationships with RRP following 2 years of treatment.
Results: Overall, RRP was significantly more likely to occur among
patients treated with MTX monotherapy (33.5%) than among patients
treated with ADAþMTX (6.7%). In the MTX-treated population, there
was an association between increasing Qs of %CRP (less improve-
ment) and RRP prevalence; 26.5%, 27.9%, 32.2%, and 48.5% in
the Q1 (98.61 - <80.34), Q2 (80.34 - <61.28), Q3 (61.28 -
<16.67), and Q4 (16.67 - þ661.36) quartiles, respectively, demon-
strated RRP. In contrast, this association was absent in the
ADAþMTX population, where the risk of RRP was universally low;
6.7%, 5.2%, 8.0%, and 6.9% in the Q1, Q2, Q3, and Q4 quartiles,
respectively, demonstrated RRP. In both treatment groups, lower CRP
improvement at week 12 was observed in the majority of patients
ultimately identified with RRP at year 2; 84% of the MTX-treated RRP
patients and 54% of the ADAþMTX-treated RRP patients exhibited
CRP improvement 80% after 12 weeks of treatment. Interestingly,
increasing Qs of CRP at 12 weeks produced comparable results to
those from the %CRP.
Conclusions: CRP changes from baseline to 12 weeks or absolute
CRP levels at 12 weeks were associated with the prevalence of RRP.
Of note, association of CRP with poor radiographic prognosis applied
mainly to patients treated with MTX monotherapy, as RRP rates were
low in patients treated with ADAþMTX and CRP changes were not
correlative with frequency of RRP during combination therapy. Based
on these data, changes in CRP or CRP levels at 12 weeks appear to
be useful tools for early identification of MTX-treated patients who will
fail to achieve long-term disease control, as evidenced by significant
radiographic damage.
Disclosure statement: P.E has receieved research grants, consul-
tancy fees or other remuneration from Abbott, Merck, Pfizer, Roche
and Bristol-Myers Squibb. B.G., H.K., N.M. and K.P. are full-time
employees of Abbott and may hold Abbott stock or stock options. E.K.
has received consultancy fees or other remuneration from Abbott,
UCB, Pfizer, Roche, Amgen and Bristol-Myers Squibb. All other
authors have declared no conflicts of interest.
216. SAFETY OF SUBSEQUENT BIOLOGIC THERAPY
IN RA PATIENTS WHO DISCONTINUED RITUXIMAB
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Background: B cell (CD20þ) depletion with rituximab (RTX) may be
long lasting, therefore the purpose of this analysis is to describe the
rate of serious infection events (SIEs) in patients treated with RTX, who
subsequently received a biologic disease-modifying antirheumatic
drugs (DMARDs).
Methods: Patients with moderate to severe, active RA receiving
RTXþmethotrexate who withdrew from clinical studies entered a
safety follow-up (SFU). During SFU, peripheral B cell counts were
monitored at regular intervals for 48 weeks and patients were
permitted to receive other biologics. SIEs, defined as serious adverse
events or infections that required IV antibiotics, were recorded
throughout the SFU.
Results: As of Sept 2009, 3189 RA patients had received 1 RTX
course, which amounted to 9342 patient-years of follow-up. Overall,
SIE rate was 4.35 (95% CI 3.94-4.79) per 100 patient-years. Of
patients who entered the SFU, 283 were subsequently treated with
another biologic (median time 8.5 [range 0.1-52] months after last RTX
infusion); most (n¼230) received TNF inhibitors. Median follow-up
after receipt of the subsequent biologic was 11 (range 7-17) months.
For the majority of patients (83%), peripheral B cell CD19 levels were
depleted below the lower limit of normal (<80 cells/L) at the time of
receiving subsequent biologic. 87 (30.7%) patients received subse-
quent biologic within 6 months of their last RTX infusion. B cell
depletion appeared to have little impact on the emergence of
infections with subsequent biologic therapy, as the proportion and
rate of SIEs was similar before and after the biologic (Table 1). Median
time to SIE after initiating biologic therapy was 11 (range 2-21) months.
In 43 patients receiving abatacept post-RTX, there was one SIE before
and after this subsequent biologic (total 97.7 patient-years). In general,
infections were typical for RA patients with no opportunistic or
fatal infections. In a subgroup analysis of 174 patients with very low
B cell counts (CD19þ count <20 cells/L) at the time of receipt of
subsequent biologic, SIE rate was 6.28 (95% CI 3.79-10.42) per 100
patient-years. In patients who received biologic <6 months (n¼87)
or 6 months (n¼196) post-RTX, SIE rates were 5.04 (95% CI 2.26-
11.22) and 4.94 (95% CI 2.66-9.18), respectively.
Conclusions: In this updated analysis, the use of subsequent bio-
logics in RA patients previously treated with RTX was not associated
with an increase in the rate of serious infections. The rate of serious
infections is consistent with rates seen in long-term safety analyses.
Disclosure statement: L.B. is an employee of Roche. A.C. is an
employee of Genentech. S.C. has received consultancy fees from
Genentech and Biogen Idec. P.E. has received research grants and
consultancy fees from Roche and Abbott. M.G. has received research
grants from Biogen Idec, Genentech and Roche, and consultancy fees
from Biogen Idec and Genentech. E.K. has received consultancy fees
from and is a member of speakers’ bureaus for Genentech, Biogen
Idec and Roche, and has received research grants from Roche. E.M.
has received research grants from Biogen Idec and Genentech. W.R.
is an employee of Genentech. T.S. is an employee of Roche and may
hold Roche stock or stock options. M.S. holds Biogen Idec stock or
stock options. All other authors have declared no conflicts of interest.
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217. ANTI-CD3 MAB INDUCES CD8þFOXP3þT CELLS
FROM THE PBMC OF RA PATIENTS
Shawn D. Ellis1, Michael R. Ehrenstein2 and Clare A. Notley2
1Medical School, UCL, London, United Kingdom; 2Centre for
Rheumatology, UCL, London, United Kingdom
Background: The use of anti-CD3 monoclonal antibody (mAb) for
the treatment of type 1 diabetes and prevention of transplant rejection
has been well studied and linked with the induction of regulatory T cell
(Treg) populations in vivo. Based on observations made in a mouse
model of rheumatoid arthritis (RA) that anti-CD3 therapy can suppress
collagen-induced arthritis (CIA), the aim was to understand its
immunomodulatory capacity in the context of RA. Suppression of
CIA was associated with the induction of CD8þFoxp3þ T cells that
were capable of regulating Th1 and Th17 responses. CD8þ Foxp3þ T
cells constitute less than 1% of peripheral CD8þ T cells in healthy and
RA patients; therefore, very little is known about their induction or their
ability to regulate immune responses. As anti-CD3 therapy is now
about to enter clinical trials for use in RA, we investigated its ability to
induce CD8þFoxp3þT cells from the peripheral blood mononuclear
cells (PBMC) of patients with RA.
Methods: PBMC were co-cultured in vitro with various doses of anti-
CD3 mAb. To understand further the conditions required for the
induction of CD8þ Foxp3þT cells, the role of TNF alpha, TGF beta
and IL-6 were determined by adding neutralising antibodies to in vitro
induction assays. Depletion assays were used to ascertain the origin of
the cytokines responsible for the induction of CD8þ Foxp3þT cells
in vivo.
Results: Co-culture of PBMC with low dose anti-CD3 mAb resulted
in optimal induction of CD8þFoxp3þ T cells. These cells did
not express the transcription factor Helios, suggesting they are
induced and not expanded from pre-existing peripherally derived
CD8þFoxp3þT cells. Furthermore, they expressed high levels of TNF
Receptor 2 (TNFR2) and CD25 and produced negligible amounts of
IFN gamma and IL-2. These are characteristics of Tregs rather than
activated T cells. Co-culture of RA PBMC with anti-CD3 mAb and anti-
TGF beta mAb or anti-IL-6 mAb revealed that neither TGF beta nor IL-6
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were required for the induction of CD8þFoxp3þ T cells. However,
long-term cultures suggested that IL-6 may be required for their
maintenance. In contrast, blockade of TNF alpha inhibited the
induction of CD8þFoxp3þT cells by approximately 50% (P<0.01).
Culture of PBMC depleted of monocytes with anti-CD3 mAb abolished
the production of TNF alpha and the induction of CD8þ Foxp3þ T
cells (P< 0.001), revealing that the induction of CD8þFoxp3þT cells
was entirely dependent on the presence of monocytes.
Conclusions: Weak stimulation of PBMC from RA patients with anti-
CD3 mAb can potently induce CD8þFoxp3þT cells that have a
similar phenotype to CD4þTregs. Their induction is dependent on the
presence of monocytes and the production of TNF alpha. The
induction of CD8þFoxp3þT cells by anti-CD3 mAb has the potential
to be harnessed therapeutically, provides insight into its mechanism of
action and could be used as a predictor of patients who will respond
successfully to anti-CD3 mAb.
Disclosure statement: The authors have declared no conflicts of
interest.
218. THE ROSE STUDY: EFFICACY AND SAFETY OF
TOCILIZUMAB IN RA PATIENTS WITH PREVIOUS
INADEQUATE RESPONSE TO DMARDS
Yusuf Yazici1, Jeffrey Curtis2, Akgun Ince3, Herbert Baraf4,
Raymond Malamet5, Carol Y. Chung5 and Arthur Kavanaugh6
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Background: Early and aggressive treatment of RA is associated with
improved disease outcomes. The 24-week Rapid Onset and Systemic
Efficacy (ROSE) study enrolled patients with moderate to severe RA
and inadequate response to DMARDs (DMARD-IR) to assess the
efficacy of tocilizumab (TCZ)þDMARDs for the reduction of RA signs
and symptoms.
Methods: Patients (N¼619) were randomly assigned to receive TCZ
8 mg/kg (n¼412) or placebo (n¼ 207), in combination with DMARDs,
for 24 weeks. Patients were assessed every 4 weeks, with the primary
efficacy endpoint ACR50 response at Week 24. A subset of 62 patients
was assessed for disease activity at Week 1. Safety and laboratory
assessments continued throughout the study.
Results: More patients in the TCZ group achieved the primary
endpoint vs patients in the control group (30.1% vs 11.2%,
p<0.0001). ACR20 and ACR50 response rates between Weeks 4
and 24 were significantly higher for TCZ patients, while the ACR70
response rate was significantly higher in the TCZ group from Week 8
until Week 24. Significant improvements in RAPID3 scores were
evident in the TCZ group from Week 4 to Week 24 and in FACIT-
Fatigue scores from Week 8 through Week 24. Early improvements in
CRP and Hb in the TCZ group at Week 4 were sustained through Week
24, with significant CRP improvement maintained throughout the study
(p<0.0001). TCZ-treated patients assessed at Week 1 demonstrated
significant improvements in DAS28, patients’ pain and global assess-
ment scores and normalised CRP levels (p 0.01 vs control). SAE
rates/100PY (95% CI) were 24 (17, 33) in the TCZ group and 19 (11, 31)
in the control group. Serious infections occurred in 2.9% and 0.5% of
patients in the TCZ and control groups and malignancies were
reported in 0.7% and 1.5% of patients. ALT shifts to>3ULN
occurred in 3.2% and 1.1% of TCZ and control patients. Grade 3/4
decreases in neutrophil counts were reported in 2.9% of TCZ patients
vs 0% of controls. There were no Grade 3/4 decreases in platelet
counts.
Conclusions: Significant benefits of TCZ in reducing disease activity
were demonstrated as early as Week 4, with DAS28 improvements as
early as Week 1 and sustained improvements over 24 weeks. Safety
findings were consistent with the known safety profile of TCZ. These
results demonstrate the early and sustained efficacy of TCZ,
confirming it as an effective treatment option for DMARD-IR RA
patients
Disclosure statement: H.B. has received research grants from
Roche. C.C. and R.M. are employees of Genentech, a member of
the Roche Group. J.C. has received research grants from Amgen, Inc.,
Centocor, Inc., Corrona and Roche, consultancy fees from Centocor,
Inc., Corrona, Roche and UCB, Inc., and is/has been a member of
speakers’ bureaus for Roche and UCB, Inc. A.I. is/has been a member
of speakers’ bureaus for Abbott Laboratories, Amgen, Inc. and Wyeth
Pharmaceuticals. A.K. has received consultancy fees from and carried
out clinical research on behalf of Roche. Y.Y. has received consultancy
fees from Bristol-Myers Squibb, Celgene, Centocor, Corrona, Roche
and UCB, has received research grants from Centocor, Corrona and
Roche, and is/has been a member of speakers’ bureaus for Bristol-
Myers Squibb, Roche and UCB.
TABLE 1.
ACR20 ACR50 ACR70
Week TCZ Control p TCZ Control p TCZ Control p
4 34.2 17.6 <0.0001 12.5 3.4 0.0002 4.4 1.5 0.0627
8 46.5 25.4 <0.0001 20.8 5.4 <0.0001 6.8 0.5 0.0002
24 44.7 25.4 <0.0001 30.1 11.2 <0.0001 15.4 1.5 <0.0001
RAPID3 score* FACIT-fatigue score* CRP, mg/dly
4 1.27 0.52 <0.0001 3.97 2.99 0.0152 0.41 1.71 <0.0001
8 1.70 0.75 <0.0001 5.71 3.72 0.0110 0.28 1.72 <0.0001
24 2.30 1.37 <0.0001 8.49 5.76 0.0188 0.25 1.37 <0.0001
*Adjusted mean change from baseline. yMean values, p based on change from
baseline
219. TARGETING THERAPEUTICS TO ARTHRITIC JOINTS
Chris Hughes1, Bjarne Faurholm1, Francesco Dell’Accio1,
Antonio Manzo1, Michael Seed1, Noha Eltawil1, Alessandra Marrelli1,
David Gould1, Christina Subang1, Adam Al-Kashi1, Cosimo De Bari2,
Paul Winyard3, Yuti Chernajovsky1 and Ahuva Nissim1
1Barts and The London School of Medicine and Dentistry, Queen
Mary University of London, London, United Kingdom; 2School of
Medicine & Dentistry, University of Aberdeen, Aberdeen,
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Background: The aim of our study is to target anti-inflammatory
proteins to arthritic joints, in order to improve efficacy and reduce side-
effects of current therapies.
Methods: We chose type II collagen (CII) as a target as it is uniquely
present in cartilage. In the arthritic joint, CII is damaged by reactive
oxidant species (ROS) generated in the inflammation process. We
used ROS-modified CII to select a single chain antibody (scFv) specific
to ROS-CII. In order to target therapeutic proteins to the inflamed
joints, we have fused anti-ROS-CII scFv to anti-inflammatory proteins
via an MMP cleavage site linker. MMPs are up-regulated in arthritis,
and therefore when the fusion protein is localised to inflamed areas by
the scFv, the therapeutic is liberated, and is free to engage its target.
Results: We were able to demonstrate binding of this scFv, 1-11E to
damaged cartilage from rheumatoid arthritis (RA) and osteoarthritis
(OA) patients but not to intact cartilage.
Accordingly, imaging studies have shown that fluorescently
labelled 1-11E scFv localises specifically to inflamed joints in arthritic
mice. 1-11E fused to mTNFR2-Fc is able to bind modified CII in ELISA,
and is cleaved at the linker site by incubation with MMP-1. Biological
activity of the fusion protein was also demonstrated in vitro. Moreover,
we show that by fusing mTNFR2-Fc to 1-11E, the therapeutic efficacy
in arthritic mice is enhanced.
Conclusions: We have a proof of principle that therapeutics targeted
by anti-ROS-CII to the joints have augmented anti-inflammatory
properties. Future work will involve optimising the fusion proteins
with a view to development towards the clinic, including targeting
alternative therapeutic molecules.
Disclosure statement: The authors have declared no conflicts of
interest.
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Background: To evaluate the long-term safety of rituximab (RTX) in
RA patients (pts).
Methods: Pooled observed case analysis of safety data from pts
treated with RTXþmethotrexate in a global clinical trial programme.
Pts were offered RTX retreatment based on physician decision of
clinical need and criteria for retreatment included assessment of active
disease (either SJC and TJC 8 or DAS28 2.6). Pts who received
placebo during placebo-controlled study periods were pooled to
provide a placebo population.
Results: As of September 2009, 3189 pts had been treated with RTX
providing 9342 pt-yrs exposure. Over 1500 pts were followed for >3
yrs and 587 pts for >5 yrs with 2417, 1724, 1392, 1036 and 656 pts
receiving 2, 3, 4, 5 and 6 courses, respectively; some pts had
>9 yrs of follow-up with up to 15 courses of RTX. Other than infusion-
related reactions (IRRs), the safety profile of RTX was similar to the
placebo population. In RTX pts, the most frequent AEs were IRRs;
most were CTC grade 1 or 2 and occurred after the first infusion of the
first course (23.0%) with 0.5% considered serious (over all courses).
SAE and infection rates generally remained stable over time and
over multiple RTX courses, and in pts in long-term follow-up (Table 1).
The overall serious infection rate was 4.35 events/100 pt-yrs (3.19
events/100 pt-yrs in pts treated for >5 yrs) and was comparable to that
observed in the placebo population (4.29 events/100 pt-yrs). Lower
respiratory tract infection, predominantly pneumonia (2%), was the
most frequent serious infection. Serious opportunistic infections were
rare, with the rates comparable between RTX and placebo (0.04 and
0.1 events/100 pt-yrs, respectively). Rates of myocardial infarction
(0.49 events/100 pt-yrs) and stroke (0.25 events/100 pt-yrs) were
consistent with rates in the general RA population (0.48-0.59 and
0.51-0.76 events/100 pt-yrs, respectively) [1-4].
Conclusions: In the long-term follow-up of RA pts treated with RTX in
clinical trials, no new safety signals were observed in all exposed pts,
including pts with >5 yrs of follow-up. RTX has remained well tolerated
over time and over multiple courses, with a safety profile similar to that
of the pooled placebo population and consistent with published data
on pts with moderate to severe RA.
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and Regeneron. D.F. has received consultancy fees from Actelion,
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16.2 (15.4, 17.0) 15.5 (14.2, 16.9) 15.5 (13.2, 18.2)
Infection rate/
100 pt-yrs (95% CI)




4.35 (3.94, 4.79) 3.19 (2.64, 3.85) 4.29 (3.17, 5.80)
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221. LITHE THREE-YEAR RESULTS: INHIBITION OF
RADIOGRAPHIC PROGRESSION AND IMPROVEMENT
IN PHYSICAL FUNCTION WITH TOCILIZUMAB IN
RA PATIENTS
Joel M. Kremer1, Daniel E. Furst2, Ruben Burgos-Vargas3,4,
Jean Dudler5, Christopher M. Mela6, Emma Vernon6 and
Roy M. Fleischmann7
1Rheumatology, Albany Medical College, Albany, NY, USA;
2Rheumatology, UCLA Medical Center, Los Angeles, CA,USA;
3Rheumatology, Hospital General de Mexico, Mexico City, Mexico;
4Rheumatology, Universidad Nacional Auto´noma de Me´xico, Mexico
City, Mexico; 5Rheumatology, Hoˆpital orthope´dique, Lausanne,
Switzerland; 6Rheumatology, Roche, Welwyn, United Kingdom;
7Rheumatology, Metroplex Clinical Research Center, Dallas, TX, USA
Background: LITHE is a Phase III randomised double-blind study
comparing the safety and efficacy of tocilizumab (TCZ) vs placebo
(PBO) in patients (pts) with moderate-to-severe active RA and
inadequate response to methotrexate (MTX).
Methods: 1,190 pts were randomised to receive TCZ (4 mg/kg [TCZ4]
or 8 mg/kg [TCZ8]) or PBO every 4 wks, all with MTX 10-25 mg/wk. In
Yr 2 pts could switch to open-label TCZ8. Hand and feet radiographs
were analysed by Genant-modified Total Sharp Score (GmTSS) from
all pts with baseline (BL), Wk 52, Wk 104, and at least one post-Wk 104
radiograph (linear extrapolation was used if a pt had a post-Wk 104 but
not a Wk 152 value). Pooled data are reported for all pts who received
1 TCZ dose (All TCZ). Data from the first TCZ dose to 28 Aug 2009
are presented (mean treatment duration 2.43y). LOCF was used for
missing TJC/SJCs; no imputation was used for missing HAQ, CRP,
ESR and VAS.
Results: The radiographic population consists of 80% of pts
entering Year 3 with a post-Wk 104 assessment (704 pts: 244 TCZ8,
241 TCZ4, 219 PBO). Only 19% of TCZ4 and 9% of PBO pts remained
on original treatment at 1 yr. By Yr 3, most pts had received open-label
TCZ8 for 2 yrs. Most radiographic progression in the PBO group
occurred in the first year. Mean change in GmTSS was 60% lower in
patients who had initially received TCZ, and more patients in the TCZ
groups had no radiographic progression at 3 years. Signs and
symptoms and safety were assessed in 1,149 pts (All TCZ) with
2,790 pt-years’ (PY) exposure. ACR response and DAS28 remission
rates remained high, demonstrating continued clinical efficacy. The
proportion of pts with HAQ scores of <0.5 at Yr 2 was maintained
through Yr 3. SAEs and serious infection rates were 11.0 and 3.2/
100PY; overall deaths and deaths from infections were 0.39 and 0.14/
100 PY. Malignancies occurred at a rate of 0.7/100PY (solid cancers
[0.6/100PY] and non-melanoma skin cancer [n¼1; 0.0/100PY]).
Conclusions: TCZ treatment continued to inhibit radiographic
progression. Improvements in physical function and clinical responses
were maintained. The safety profile is consistent with the 2-yr analysis.
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TABLE 1. Outcomes, Week 152
GmTSS TCZ8 n¼ 244 TCZ4 n¼ 241 Control n¼219
Mean (S.D.) change from BL 0.72 (2.56)*,y 0.71 (2.14)y,z 1.78 (3.64)
Pts with no progression
(GmTSS change from
BL 0), % (n)
69 (169)*,x 67 (162)x,k 51 (111)
Signs and Symptoms All TCZ
ACR20, % (n/n) 80 (472/591)
ACR50, % (n/n) 59 (346/591)
ACR70, % (n/n) 36 (212/591)
DAS28 remission, % (n/n) 57 (325/572)
TJC and SJC¼ 0, % (n/n) 21 (137/656)
HAQ<0.5 % (n/n) 37 (202/552)
n/n: no. patients achieving end point/no. patients reaching timepoint with valid
assessments. *p< 0.0001 vs control. yp calculated by Van Elteren test stratified by
region. zp¼ 0.0002 vs PBO. xp calculated by logistic regression analysis adjusted
for region. kp¼ 0.0008 vs control.
222. PEPTIDYLARGININE DEIMINASE FROM
PORPHYROMONAS GINGIVALIS AS A POTENTIAL
TARGET FOR THE TREATMENT AND PREVENTION OF
RHEUMATOID ARTHRITIS
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Background: Porphyromonas gingivalis (P. gingivalis) is a major
bacterium in the pathogenesis of periodontitis. Several epidemiologi-
cal studies have shown an association between periodontitis and
rheumatoid arthritis (RA). We demonstrated cross-reactivity between
citrullinated human a-enolase and P. gingivalis enolase, and that the
anti-citrullinated a-enolase response links with DR4 alleles and
smoking, common susceptibility factors for RA and periodontitis.
Recently, we reported that P. gingivalis peptidylarginine deiminase
(PPAD) catalyses the citrullination of carboxy-terminal arginines to
citrulline, in both bacterial and human peptides. Bacterial citrullination
might therefore be aetiologically important in a subset of RA by driving
the autoimmune response to citrullinated proteins. Hence, we
investigated the PPAD enzyme as a potential new therapeutic target.
Methods: Recombinant full-length PPAD was expressed in E. coli,
purified, and tested for enzymatic activity. A specific antibody to PPAD
was developed by immunising rabbits with recombinant protein. The
subcellular localisation of PPAD was investigated by fractionation of
P. gingivalis and blotting with anti-PPAD antibody. Cross-reactivity
with human PADs was examined by western blot. PPAD inhibition
studies were performed using tetracycline, doxycycline, minocycline,
sulfasalazine, methotrexate, and 2-chloroacetamidine. Site-directed
mutagenesis was performed to investigate the contribution of a
conserved cysteine residue to enzyme activity.
Results: Full-length PPAD was active and citrullinated a-enolase and
fibrinogen peptides harbouring carboxy-terminal arginines, but not
peptides with internal arginines. Blotting of subcellular fractions with
a PPAD-specific antibody demonstrated that the enzyme is located
on the cell surface of various P. gingivalis strains. Anti-PPAD antibody
did not cross-react with human PADs. 2-chloroacetamidine proved
an effective inhibitor with half-maximal inhibition (IC50) at 25M.
Tetracycline, doxycycline, minocycline, sulfasalazine or methotrexate
did not inhibit PPAD activity. The substitution of cysteine-351 with
alanine completely abolished PPAD activity.
Conclusions: The cell-surface localisation identifies PPAD as a
putative virulence factor and suitable pharmaceutical target.
Cysteine-351 as a crucial catalytic residue indicates that agents
targeting cysteines can be effective inhibitors. This is confirmed by the
inhibitory activity of 2-chloroacetamidine in the low M-range. Our
combined results suggest that PPAD and human PADs have different
three-dimensional structures but share a similar, although not
identical, catalytic mechanism. Our findings form the basis for further
characterisation, such as crystallisation and the development of more
potent and specific inhibitors with the potential to prevent RA by
inhibiting the generation of the autoantigens which drive the disease.
Disclosure statement: The authors have declared no conflicts of
interest.
Scleroderma and related disorders
223. LONG TERM OUTCOME IN A CONTEMPORARY
SYSTEMIC SCLEROSIS COHORT
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1Centre for Rheumatology and Connective Tissue Diseases,
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Background: We have previously compared outcome in two groups of
systemic sclerosis (SSc) patients with disease onset a decade apart
and we reported data on 5 year survival and cumulative incidence of
organ disease in a contemporary SSc cohort. The present study
examines longer term outcome in an additional cohort of SSc followed
for 10 years.
Methods: We have examined patients with disease onset between
years 1995 and 1999 allowing for at least 10 years of follow-up in a
group that has characteristics representative for the patients we see in
contemporary clinical practice.
Results: Of the 398 patients included in the study, 252 (63.3%) had
limited cutaneous (lc) SSc and 146 (36.7%) had diffuse cutaneous (dc)
SSc. The proportion of male patients was higher among the dcSSc
group (17.1% v 9.9%, p¼ 0.037) while the mean age of onset was
significantly higher among lcSSc patients (50 13 v 4613
yearsSD, p¼0.003).
During a 10 year follow-up from disease onset, 45% of the dcSSc
and 21% of the lcSSc subjects developed clinically significant
pulmonary fibrosis, p<0.001. Among them approximately half
reached the endpoint within the first 3 years (23% of dcSSc and
10% of lcSSc) and over three quarters within the first 5 years (34% and
16% respectively). There was a similar incidence of pulmonary
hypertension (PH) in the two subsets with a steady rate of increase
over time. At 10 years 13% of dcSSc and 15% of lcSSc subjects had
developed PH (p¼0.558), with the earliest cases observed within the
first 2 years of disease. Comparison between subjects who developed
PH in the first and second 5 years from disease onset demonstrated
no difference in demographic or clinical characteristics, but 5-year
survival from PH onset was better among those who developed this
complication later in their disease (49% v 24%), with a strong trend
towards statistical significance (p¼0.058). Incidence of SSc renal
crisis (SRC) was significantly higher among the dcSSc patients (12% v
4% in lcSSc, p¼0.002). As previously observed, the rate of
development of SRC was highest in the first 3 years of disease-
10% in dcSSc and 3% in lcSSc. All incidences of clinically important
cardiac disease developed in the first 5 years from disease onset
(7% in dcSSc v 1% in lcSSc, p< 0.001) and remained unchanged at
10 years. As expected, 10-year survival among lcSSc subjects
was significantly higher (81%) compared to that of dcSSc patients
(70%, p¼0.006). Interestingly, although over the first 5 years the death
rate was much higher in the dcSSc cohort (16% v 6% in lcSSc), over
the following years it became very similar for both subsets (14% and
13% between years 5 and 10, and 18% and 17% between years 10
and 15 for dcSSc and lcSSc respectively).
Conclusions: Even though dcSSc patients have higher incidence for
most organ complications compared to lcSSc subjects, the worse
survival among them is mainly due to higher early mortality rate.
Mortality rate after first 5 years of disease becomes comparable in
the two disease subsets.
Disclosure statement: The authors have declared no conflicts of
interest.
224. SYSTEMIC SCLEROSIS MANAGEMENT: ARE WE
DOING AS WELL AS WE COULD?
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Background: 2009 EULAR guidelines set clear standards for the
treatment of systemic sclerosis (SSc). We wanted to assess our
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